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Abstract
Transcription factor E2F plays an important role in orchestrating early cell cycle 
progression through its ability to co-ordinate and integrate the cell cycle with the 
transcriptional apparatus. Physiological E2F arises when members of two distinct 
families interact as E2F-DP heterodimers, in which the E2F component mediates 
transcriptional activation and physical interaction with pocket proteins, such as the 
tumour suppressor protein pRB. However, very little information is available regarding 
the mechanisms, which control the levels of functional E2F. In this study I have 
defined the DP component as an integrator of the E2F transcription factor with the 
nuclear transport pathway and the ubiquitin-proteasome mediated degradation pathway. 
Specifically, a bipartite nuclear localisation signal in DP is defined and shown to be 
necessary for nuclear accumulation of a non-NLS-containing heterodimeric partner. 
Pocket protein association also offers an alternative in trans NLS for translocation of 
the heterodimer into the nucleus. Suiprisingly, the basic region of the NLS is also 
necessary for efficient nuclear accumulation of NLS-containing E2F heterodimeric 
partners. The basic region is also instrumental in the association of DP-3 with the 
epsilon isofonn of the 14-3-3 family of signalling molecules. Using a mutant DP that 
fails to bind 14-3-3 has uncovered a role for 14-3-3 in the E2F pathway. An association 
targets the E2F heterodimer for ubiquitin-proteasome-mediated degradation to reduce 
excessive levels of E2F and allow cells to progress into G2 phase of the cell cycle. This 
study defines new pathways of growth con4rôl"that are integrated with the E2F pathway 
through the DP subunit.
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Chapter 1. Introduction
1-1. The E2F pathway
Understanding normal cell cycle control is essential when searching for novel 
anti-tumour therapeutics. The deregulation of proliferation of a malignant cell is caused 
by small alterations in the machinery that directs normal cell growth and division. This 
machinery has the ability to continuously monitor the status of the intra-cellular and 
extra-cellular environment in order to maintain the integrity of the genome during each 
cell division cycle. The transition from G1 to S phase is a particularly important period 
when critical choices, resulting in cell growth or quiescence, are made. Progression into 
S phase is tightly coupled to the transcriptional control of genes involved in growth and 
DNA replication (Dyson, 1998) (Figure 1.1). The E2F family of transcription factors 
principally cames out this temporal control of gene expression. The pathway 
responsible for regulating E2F is frequently found to be aberrant in human tumour cells, 
thus, comprehension of the mechanisms involved in regulating the E2F pathway will 
provide an insight into the workings of the molecular machinery that controls cell 
proliferation and consequently present suitable targets for anti-cancer therapies.
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Figure 1.1
E2F regulated genes
(A) Table showing genes involved in DNA synthesis, cell proliferation and 
apoptosis that are regulated by E2F through E2F DNA binding sites within their promoter 
regions.
1-1.1. The E2F family of proteins
The E2F family comprises of two distinctly related subfamilies, E2F and DP. 
One subunit of E2F and one subunit of DP combine to form a transcriptionally active 
E2F heterodimer (La Thangue, 1994; Lam and La Thangue, 1994; Wu et al., 1996). To 
date, six E2F genes and three DP genes have been identified (Helin et al., 1992; Kaelin 
et al., 1992; Shan et a l, 1992; Ivey-Hoyle et al,, 1993; Lees et al., 1993; Beijersbergen 
et al., 1994; Ginsberg et al., 1994; Sardet et al., 1995; Hijmans et al., 1995; Morkel et 
al., 1997; Cartwright et al., 1998; Trimarchi et al., 1998; Girling et al., 1993; 
Ormondroyd et al., 1995; Wu et al., 1995; Zhang and Chellapan, 1995; Rogers et al.,
1996) (Figure 1.2). E2F-1, -2, -3, -4 and -5  share 20%-50% identity and have a similar 
organisation of functional domains but E2F-6 lacks a transactivation domain (Morkel et 
al., 1997). The DPs are highly homologous (-70%), and each can form a functional 
heterodimer with any E2F family member. E2F and DP proteins contain highly 
conserved DNA-binding and dimérisation domains (Helin, 1998) (Figurel.2). The 
crystal structure of an E2F-4/DP-3/DNA complex shows that the DNA-binding 
domains of the E2F and DP proteins both have a fold related to the winged-helix DNA- 
binding motif and that heterodimerisation aids DNA binding (Zheng et a l, 1999).
Expression of the E2F family can be observed in a wide range of tissues and cell 
lines. The levels of mRNA expression are highly variable and to some extent, tissue 
restricted (Wu et al., 1995). Synthesis of E2F-1 mRNA is induced in mid-Gl and 
reaches its highest levels in S phase (Slansky et al., 1993). In fibroblasts, E2F-4 and 
E2F-5 transcripts are abundant in GO, with E2F-4 expressed considerably higher than
18
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DP 3a
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DP-3Ô
E2F similarity
Figure 1.2
The structures of the E2F and DP family members.
(A) Summary o f  the structures o f  the E2F family members E 2Fs-l,-2,-3,-4,-5  
and -6, indicating the locations o f  the conserved domains.
(B) Summary o f  the structures o f  the DP family members D P -1,-2 and -3 
indicating the position o f  the conserved region with greatest similarity to E2F family 
members.
E2F-5 in these quiescent cells (Sardet et a l, 1995). Following neuronal differentiation, 
E2F-4 is highly up regulated, while E2F-1, -3 and 5 are down regulated. E2F-5 is up 
regulated in certain differentiated tissues (Dagnino et al., 1997). DP-1 is a frequent 
component of E2F, occurring in most forms of the DNA binding activity in many 
different cell types. The induction of DP-1 mRNA in mid-Gl is almost identical to the 
induction of E2F-4, although DP-1 mRNA levels do not decrease during S phase 
(Sardet et ah, 1995). DP-2 and DP-3 are less frequent components of E2F and their 
expression is tissue-restrictive (Girling et a l, 1994; Rogers et a l, 1996).
1-1.2. The pRB/E2F complex
The best-studied upstream regulators of E2F are the retinoblastoma family of 
proteins, or ‘pocket proteins’, which include pRB, pl07, and pl30  (Bartek et a l, 1996; 
Sidle et a l, 1996). A short, highly conserved domain near the carboxyl-terminus of the 
E2F proteins mediates binding to pRB family proteins (Flelin et a l, 1993) (Figurel.2). 
This binding domain is embedded in the fra/r^-activation domain of the E2F subunit, 
suggesting a model for inhibition of E2F-dependent /rany-activation without affecting 
DNA binding ability (Flemington et a l, 1993; Zamanian and La Thangue, 1993; Helin 
et a l, 1993). Consistent with the lack of a /mMJ-activation domain, E2F-6 is unable to 
bind to pocket proteins (Trimarchi et a l, 1998). The ability of pRB and related proteins 
to repress E2F activity coiTelates with their growth suppression function, and intrinsic 
capacity to repress transcription (Bremner et a l,  1995; Zhang et a l, 1999), suggesting 
that E2F repression may be an essential element of pRB-mediated growth suppression 
(Helin et a l, 1993). Different members of the pRB family appear to regulate specific 
E2F family members, as pRB primarily binds to E2F-1, -2, and -3 , although it can also
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bind to E2F-4 (Ikeda et al., 1996; Moberg et al., 1996). In contrast, p i07 and p i30 
display higher affinities toward E2F-4 and -5  (Beijersbergen et al., 1994; Ginsberg et 
a l, 1994; Sardet et al., 1995; Vairo et al., 1995). As a general rule, pRB/E2F 
complexes can be found in quiescent or differentiated cells, but are most evident as cells 
progress from G1 into S phase. pl07/E2F complexes are most prevalent in S phase 
cells but can also be found in G l. In mid- to late-Gl the complex also contains cyclin 
E/cdk2, which is exchanged for cyclin A/cdk2 in S phase. pl30/E2F complexes replace 
pl07/E2F complexes when cells exit the cell cycle and differentiate (Smith et al.,
1997). Based on these findings it has been suggested that different E2F members, 
together with their primary pRB protein regulators, control different sets of genes at 
different stages of the cell cycle.
1-1.3. Regulation of the pRB/E2F association
Regulation of the physical interaction between pRB and E2F is integrated with 
cell cycle progression. In G l pRB exists in an active, hypophosphorylated state and is 
complexed with E2F. At the Gl/S transition, cyclin D/Cdk4 then cyclin E/Cdk2 or 
cyclin A/Cdk2 complexes sequentially phosphorylate pRB, thereby reducing its affinity 
for E2F (Mittnacht 1998; Harbour et a l, 1999). Release of free E2F allows activation 
of transcription of genes required for S phase entry and progression (Figure 1.3).
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REPRESSING
COMPLEX
INHIBITING
COMPLEX
ACTIVATING
COMPLEX
INACTIVE
COMPLEX
Figure 1.3 
The E2F pathway
(A) Model showing different E2F complexes that occur as cells progress through 
the cell cycle: repression com plexes recruit RB-family proteins to the DNA, inhibited 
com plexes arise when the binding o f  RB to E2F physically blocks the activityof the 
E2F transactivation domain, activating com plexes occur when RB-fam ily proteins are 
phosphorylated by cdks and subsequently loss their affinity for E2F, inactive com plexes 
lose their affinty for DNA upon phosphorylation o f  the DP com ponent by Cdk2.
The E2F/pRB complex is also subject to regulation by cdk inhibitors (CKTs), 
which ensure aiTest or withdrawal from the cell cycle in response to anti-mitogenic or 
genotoxic stimuli, or as part of programmes of terminal differentiation (Harper and 
Elledge, 1996). The INK4 family of CKIs are particularly important in the regulation of 
pRB. This family includes pl5, pl6, p l8 and p l9  that inhibit complexes of cyclin D l, 
2, and 3 bound to Cdk4 and Cdk6 to maintain pRB in an active state, thereby, holding 
cells in G1 (Shen* and Roberts, 1995). The importance of this function of p l6  is 
underscored by the fact that pl6-induced cell cycle arrest requires functional pRB 
(Lukas et aL, 1995). The Kip family of CKIs includes p21, p27, and p57, and can 
inhibit a wider range of Cdks including Cdk2 (Harper and Elledge, 1996), The 
importance of CKIs in the E2F pathway has been shown by knock-out mice: cells that 
have lost p l6  become immortalised (Serrano et al., 1996) and those that have lost p21 
fail to respond to DNA damage (Leder et aL, 1995). Mice lacking p27 have an increase 
in cell numbers in many tissues due to an increase in proliferation, and develop pituitary 
tumours and retinal abnormalities, reminiscent of Rb~l heterozygotes (Fero et aL,
1995).
pRB/E2F complexes represent only a minor fraction of the total E2F complexes 
present in cell extracts as E2F is not completely deregulated in the absence of pRB. In 
an attempt to separate the functions of different pocket protein members, primary 
mouse cells lacldng a specific family member were studied. The Rb-/- embryos die 
E13-15 with cells failing to attain a fully differentiated state. Additionally, ectopic cell 
cycle entry and increased levels of apoptosis are apparent in some tissues (Clarke et aL, 
1992; Jacks et aL, 1992). Rb~A mouse embryo fibroblasts (MEFs) proceed into S phase 
eaiiy but most E2F target genes are induced in time for S phase (Herrera et aL, 1996).
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No differences were observed in p i  07-/- or p i 30-/- cells unless both genes were 
targeted. The p i 07-/-', p i 30-/- double knock-out mice die in utero due to cartilage and 
bone malformation (Cobrinik et aL, 1996). However, extensive functional overlap has 
been shown to occur between p i07 and pRB as pRB-/-; p i07-/- double knock-out 
embryos die 2 days earlier than pRB-/-embryos whilst pl07-deficient mice do no show 
embryonic lethality (Lee et aL, 1996). A certain degree of redundancy must occur 
between pl07 and pl30 but not between pRB and pl07/pl30 (Hurford et aL, 1997). 
Until it is possible to confidently identify E2F complexes at endogenous promoters, it 
will remain unknown if the compensatory effects observed in knock-out mice are a true 
reflection of functional redundancy that occurs between pRB family members in normal 
cells.
1-1.4. E2F-site dependent transcription
It is not yet clear whether different E2F complexes differ in their DNA sequence 
specificity and in their preference for promoters of different E2F-responsive genes in 
vivo. Most current models rely on the assumption that results seen in over-expression 
assays in tissue culture cells reflect the properties of the endogenous proteins. Using in 
vitro assays and over-expression systems, all E2F heterodimers will bind to double­
stranded DNA encoding the general consensus sequence TTTc/gGCGCg/c (Lees et aL, 
1993; Buck et aL, 1995; Zhang and Chellappan, 1995). A model connects changes in 
gene expression to the binding of specific E2F complexes: activating complexes, in 
which the ïran^-activation domain drives transcription; inhibited complexes, in which 
the activation domain is masked by pRB family proteins; and repression complexes, in 
which pRB family proteins, and consequently hi stone deacetylases are recruited to the
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DNA by E2F, leading to local remodelling of the chromatin structure to make it less 
accessible to transcription factors (Luo et aL, 1998; Ferreira et aL, 1998; Harbour et aL, 
1999) (Figurel.3). An alternative model to explain pRB-mediated active transcriptional 
repression proposes that pRB interacts directly with TFIIA and TFIID of the basal 
transcription initiation machinery. It is possible that both repression mechanisms occur 
since some promoters tested were insensitive to HD AC 1-mediated inhibition (Luo et 
ah, 1998) and it has been shown that pRB is able to repress transcription in a 
reconstituted in vitro transcription system lacking histones (Dynlacht et al., 1994). E2F 
binding sites appear to confer specificity for an activating or a repressing complex since 
mutation of the E2F binding site in the dhfr promoter reduces DHFR expression (Means 
et aL, 1992), whereas mutation of the E2F binding site in the promoter of B-myb 
increases expression of that gene up to wild type levels (Lam and Watson, 1993). Many 
of the studies of transcriptional activation by E2F use simple promoter constructs 
containing single E2F sites, however, E2F sites are generally found in considerably 
more complex promoter regions. The pl07 promoter, for example, contains two E2F 
sites that cooperatively regulate pl07 expression (Zhu et aL, 1995). In the Ran BPl 
promoter, two E2F sites actually exert opposite functions whereby E2F-1 preferentially 
binds to one site with Spl to up-regulate gene expression, and the other site holds E2F- 
4/pocket protein complexes that repress the activity of the promoter. In another 
example, an ATF site flanks the two E2F sites in the adenovirus E2a promoter (Loeken 
et aL, 1989) and E2F-1, -2 and -3 have been shown to bind to Spl (Karlseder et aL,
1996), therefore, E2F and/or pRB may influence flanking transcription factors. Also, it 
is noteworthy that over 50 other proteins are known to interact with pRB and thus 
potentially be recruited to the E2F/DNA complex to regulate the basal transcription 
machinery.
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1-1.5. Inactivating E2F
Inactivation of E2F by pRB only occurs while pRB is in a hypophosphorylated 
state in G l, therefore, other mechanisms are needed to switch off the activity of E2F 
later in the cell cycle. If constitutively active E2F is expressed, then cells will arrest in 
S phase suggesting that down-regulation of E2F is required for cells to exit S phase 
(Krek et aL, 1995). To this end, E2F-1, E2F-2 and E2F-3 contain a conserved motif 
that mediates stable association with cyclin A/cdk2 or cyclin E/cdk2 (Krek et aL, 1994) 
(Figure 1.2). Kinases bound through this domain to an E2F/DP heterodimer 
phosphorylate both the E2F and the DP subunits, and phosphorylation by cyclin A/cdk2 
will inhibit DNA-binding activity (Ki*ek et aL, 1994, 1995) (Figure 1.3). This down- 
regulation will not occur until late S phase when cyclin A becomes activated. 
Preventing cyclin A from binding to and mediating phosphorylation of E2F/DP is 
sufficient to prevent cells from passing through S phase (Ku’ek et aL, 1995).
Ubiquitin-proteasome mediated degradation of E2F may also contribute to the 
down-regulation of E2F in S phase. Ubiquitination requires sequences within the trans- 
activation/pRB binding domain of E2F and therefore, binding to pocket proteins 
increases the stability of E2F by blocldng access to ubiquitin conjugating enzymes 
(Martelli and Livingston, 1999). Recently the degradation of E2F-1 was shown to be 
linked to a specific interaction between E2F-1 and the F-box -containing protein Skp2, 
which is the cell-cycle-regulated component of the ubiquitin-protein ligase SCF^^^ that 
recognizes substrates for this ligase (Marti et al 1999).
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1-1.6. Physiological functions of E2F
The importance of E2F in cell cycle regulation has been illustrated in several 
ways. For instance, over-expression of E2F is sufficient to induce S phase in cells held 
in quiescence by serum starvation (Johnson et ah, 1993; Asano et aL, 1996; Lukas et 
aL, 1996; Wang et aL, 1998) and dominant negative mutants suggest that E2F activity 
is required for S phase entry (Wu et aL, 1996). Over-expression of E2F-1 can over-ride 
many different types of cell cycle aiTest including that induced by pl6, p21, p27, y- 
irradiation, TGFp or dominant negative cdk2 (DeGregori et aL, 1995; Schwarz et aL, 
1995; Lukas et aL, 1996; Mann and Jones, 1996). Over-expression of E2F in transgenic 
mice promotes cell proliferation and blocks some elements of differentiation (Guy et 
aL, 1996). The elevation of E2F activity dissociates the coordination of cell growth and 
proliferation during Drosophila wing development (Neufeld et aL, 1998). This ability 
to drive cells into S phase requires its DP-binding, DNA-binding and rmzij-activation 
domains, suggesting that the induction of expression of E2F target genes promotes S 
phase (Johnson et aL, 1993; Qin et aL, 1994). Consistent with the idea that E2F 
promotes cell proliferation, E2F-1, E2F-4, E2F-5, DP-1 and DP-2 have all been 
reported to score in transformation assays, either alone or in combination with an 
activated ras gene (Beijersbergen et aL, 1994; Ginsberg et aL, 1994; Johnson et aL, 
1994; Singh et aL, 1994; Jooss et aL, 1995; Xu et aL, 1995; Polanowska 2000).
As well as promoting cell proliferation, elevated levels of E2F-1 in normal cells 
can also lead to apoptosis (Shan and Lee 1994). Support for the idea of E2F mediated 
apoptosis without relying on over-expression, came from E2F-1 knock-out mice (Field 
et aL, 1996; Yamasaki et aL, 1996). Although these mice developed and reproduced
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normally, they exhibited defects in T-cell development. Smprisingly, proliferative 
failure was not observed, and in fact tumour formation was more prevalent, indicating 
that E2F-1 functions to positively regulate apoptosis and suppress cell proliferation.
Several studies have shown that E2F-1 can induce apoptosis in either a p53- 
dependent (see below) or p53-independent manner. E2F-1 induction of apoptosis in 
p53-null cells does not require the rran^-activation domain of E2F-1 (Hsieh et ah, 1997; 
Philips et aL, 1997; Lee et aL, 1998). Under these conditions, E2F-1 induces apoptosis 
by a death receptor-dependent mechanism that sensitises cells to apoptosis in response 
to tumour necrosis factor a  (TNFa) by down-regulating expression of TRAF2, thereby 
inhibiting nonnal activation of anti-apoptotic signals such as NF-kB and JNK/SAPK 
(Phillips etaL, 1999).
Depending on its level of expression or the cellular environment, E2F-1 can 
function as an oncogene or a tumour suppressor (Pierce et aL, 1999). Oncogenicity is 
demonstrated by transformation assays (Johnson et aL, 1994), the over-expression of 
E2F-1 in transgenic mice promoting tumourigenesis (Pierce et aL, 1998) and the 
absence of E2F-1 reducing tumour phenotypes resulting from the inactivation of pRB 
(Yamasald et aL, 1998). On the other hand, germline deletion leads to an increase in 
the occurrence of tumours (Yamasaki et aL, 1996), thus defining E2F-1 as a tumour 
suppressor.
Recently, it has been shown that differential regulation of E2F-1 and E2F-3 
occurs. E2F-1 DNA-binding activity accumulates as cells are stimulated to enter the 
cell cycle, but does not accumulate in subsequent cell cycles. On the other hand, E2F-3
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levels continue to cycle. The fact that immunodepletion of E2F-3 causes cycling cells 
to aiTest suggests that E2F-1 activity is only required for re-entry into the cell cycle 
from a quiescent state and that E2F-3 regulates expression of S phase genes in 
proliferating cells (Leone et aL, 1998; Wang et aL, 1998).
A link between the E2F pathway and the G2/M transition has recently been 
shown, where E2F dependent expression of cyclin A is needed in S phase to disrupt the 
ubiquitin-ligase properties of the anaphase promoting complex (APC), thus allowing the 
accumulation of cyclin B l, a key activator of the cdc2 kinase required to initiate cell 
division (Lukas, 1999).
1-1.7. Integration of E2F with the p53 pathway
In mammalian cells, the p53 tumour suppressor is the archetypal DNA damage 
checkpoint regulator. Following genomic DNA damage, E2F DNA binding activity 
increases due to stabilisation of the protein (Blattner et aL, 1999), and consequently 
increases expression of proteins involved in the DNA damage response, such as 
ribonucleotide reductase (RNR) (Filatov et aL, 1996) and p l4  (Bates et aL, 1998). 
ARF is a peptide that stabilises p53, increasing transcription of p53-responsive target 
genes. This leads to up-regulation of p21, GADD45, cyclin G, bax and MDM2, 
culminating in either cell cycle anest, to allow time for repair, or apoptosis (El-Diery et 
aL, 1993; Harper er (2/., 1993).
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1-1.8. Regulation of E2F by protein stabilisation
Recent studies have shown that E2F-1 is subject to ubiquitin-proteasome 
mediated degradation, and the carboxyl teinninus has been identified as regulating 
protein stability (Hateboer et aL, 1996). Ectopic overproduction of hypophosphorylated 
pRB can bind and stabilise E2F-1, protecting it from ubiquitination in a cell cycle 
dependent manner. In response to gamma iiTadiation, E2F-1 is stabilised in S phase, 
parallel to the accumulation of hypophosphorylated pRB (Hofferer et aL, 1999; Martelli 
and Livingston, 1999).
Like p53, E2F-1 is also subject to degradation when complexed with MDM2. 
MDM2 carries out its anti-apoptotic role by utilizing its E3 ligase-like activity to 
stimulate ubiquitin-dependent degradation of p53 (Haupt et aL, 1997; Kubbutat et aL, 
1997). MDM2-mediated lowering of the levels of E2F protein consequently switches 
the position of E2F from a pathway leading to apoptosis to one stimulating growth. 
This level of regulation of E2F by MDM2 is mediated via the DP partner (Loughran 
and La Thangue, 2000).
1-1.9. Deregulation of E2F in cancer
Considering the central role of E2F in cell cycle control, manipulation of any of 
the pathways imparting upon E2F will be sufficient for a tumour cell to deregulate E2F 
and provide a proliferative advantage (Figure 1.4).
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The pRB gene RBI is mutated in approximately 30% of all human cancers. All 
naturally occumng mutations occur within a region termed the “pocket domain”. 
Although this region is also conserved in pl07 and pl30, no mutations have been found 
in the p i07 gene, and only a few mutations of the p i30 gene, in human cancers (Vairo 
et aL, 1995; Helin et aL, 1997). Certain tumours have evolved a mechanism that allows 
them to escape from the growth-restraining regulation by pl6: a missense mutant cdk4 
found in human melanomas is unable to associate with p l6  rendering it constitutively 
active (Wolfel et aL, 1995). Indeed, the p l6  gene itself has also been found mutated. 
Deletion and loss of function mutations and promoter silencing by DNA méthylation 
are strategies used by tumour cells to thwart negative control of E2F (Merlo et aL, 
1995). Another critical regulator of pRB, cyclin D, is expressed at high levels in certain 
tumour cells. This is accomplished through gene amplification, chromosomal 
reaiTangement (Hall and Peters 1996) or mutations that prevent cyclin D degradation 
(Welcker et aL, 1996). These cells possess an abnormally active E2F due to the 
eiToneous inactivation of pRB. However, the most widespread aberration detected in 
tumour cells is mutation of p53, or inactivation through interaction with viral proteins 
(Levine 1997). The majority of tumour cells have either a mutation in the p53 gene or 
alterations in the genes encoding p53 regulatory molecules such as MDM2, ATM and 
ARF to block initiation of a checkpoint cell cycle aiTest or apoptosis.
31
Gene amplification 
Loss of p16 binding
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Figure 1.4
Major oncogenic aberrations targeting the E2F pathway
(A) Diagram showing some o f the mechanisms used by tumour cells to activate the 
E2F pathway and drive cells into S phase.
DNA tumour viruses, simian virus 40 (SV40), adenovirus, and human papilloma 
virus (HPV) are all able to induce quiescent cells to enter and progress through the cell 
cycle (Moran 1993). An infection by these viruses leads very quickly to the expression 
of their viral oncoproteins T antigen, E l a and E7. All these proteins contain a 
consensus sequence termed the LxCxE motif that directs the association of the 
oncoproteins with pRB (Figge et aL, 1988). Sequestration of pRB by a viral 
oncoprotein subverts the E2F pathway by releasing active E2F (Bandara and La 
Thangue, 1991; Li et aL, 1993; Zamanian and La Thangue 1992; 1993). Additionally, 
the human papillomavirus HPV-16 or HPV-18 E6 protein and cellular E6-AP protein 
form a complex and function as a ubiquitin ligase for p53 (Scheffner et aL, 1993), 
abolishing the noimal p53-dependent stress response.
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1-2. Nudeocytoplasmic transport
Eukaryotic cells have a need for continuous exchange of macromolecules 
between the nucleus and the cytoplasm. As nuclear proteins are synthesized in the 
cytoplasm, specific transport systems have evolved to allow proteins to be imported 
from the cytoplasm to the nucleus. Not only do all nuclear proteins need to be imported 
from the cytoplasm, but tRNA, rRNA and mRNA, which are synthesized in the nucleus, 
need to be exported to the cytoplasm where they function in translation. A double 
membrane surrounding the nucleus, tightly guards entry into and exit from the nucleus 
during interphase, Specific transport signals contribute crucially to the fidelity of 
nuclear transport to ensure that the one million macromolecules per minute actively 
transported between the nucleus and the cytoplasm of a growing mammalian cell, are 
imported or exported correctly (Ohno et al., 1998). Several experimental approaches, 
including in vitro import and export assays in higher eukaryotes, in vivo transport 
studies in frog oocytes and in yeast have been instrumental in the discovery of 
components and mechanisms of nudeocytoplasmic transport.
1-2.1. The nuclear envelope
The nucleus is sumounded by the nuclear envelope, an impermeable double 
membrane that is continuous with the rough endoplasmic reticulum. To provide access 
across this bamer, the nuclear envelope is penetrated by nuclear pore complexes 
(NPCs) (Feldherr et aL, 1984). These elaborate protein structures have a mass of -125 
MDa in higher eukaryotes (Reichelt et al., 1990) and are estimated to consist of -100
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different proteins termed nucleoporins (Doye and Hurt, 1997). In principle, the NPC 
provides a passive diffusion channel for ions, metabolites and macromolecules smaller 
than -40-60 IcDa. However, the NPC can undergo considerable changes in 
conformation to expand the diameter of the channel from -lOnm to -25nm to provide 
an aqueous channel for active transport of macromolecules greater than 40-601dDa 
(Feldherr et aL, 1984). NPCs can accommodate active transport of particles as large as 
several million Daltons in molecular weight (Dworetzky et aL, 1988).
1-2.2. Nuclear import transporters
Proteins and small ribonucleoproteins (RNPs), that need to traverse the nuclear 
membrane in order to perform their normal cellular functions, are most often recognised 
by soluble nuclear transport receptors. These receptors mediate the translocation of 
cargos through the NPC. Cargos identify themselves to the transport machinery by 
inherent signals (7/uclear Localisation Signal, NTS) that can be protein- or RNA-based 
or a composite of both. Transport signals show great variation in complexity, from 
short peptide motifs like the classical mono-partite NTS up to large protein domains, 
and even multi-component signals such as those used in U snRNA transport 
(Figure 1.5).
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Nuclear import signals 
Cargo Signal
classical signal-monopartite PKKKRKV
classical signal-bipartite KR-------KKKK
U snRNA m3 G cap
histones extended basic-rich domain
ribosomal proteins-M9 signal 40aa glycine and aromatic rich
SR proteins SR domains
Nuclear export signals
leucine rich LALKLAGLDI
M9 40aa glycine and aromatic rich
Import receptors
type signal recognised
Importin (3 / Importin a monopartite/bipartite NLS
Snurpoitin / importin P U snRNA m3 G cap
RIPa / importin p replication protein A
Importin 7 / importin p histones
Importin P eyclinNLS,RevNLS
TRNl ribosomal proteins
TRN-SR SR proteins
Export receptors i;■
CRMl/exportinl leucine-rich NES 3
Exportin-t tRNA 1CAS importin a  NES
Figure 1.5
Im port and export signals and receptors
(A) Table showing sequences that target a protein for identification by molecules of 
the nudeocytoplasmic transport system.
(B) Table showing nudeocytoplasm ic transporters and the types o f  signals 
they recognize.
These NLSs are recognised by one or more of the nuclear import receptor family 
(Figure 1.5). Members of this family have been given various names including, 
karyopherins (Radu et aL, 1995), p97 (Chi et aL, 1995), PTACS (Imamoto et aL, 1995), 
importins (Gorlich et aL, 1995) and transportins (Pollard et aL, 1996). Different types 
of NLS are known to utilise distinct receptors (Nadler et aL, 1997). The transportin 
receptor molecule mediates nuclear translocation of glycine rich M9-NLS-bearing 
cargos (Siomi and Dreyfuss, 1995; Michael et aL, 1995). Three classes of cargo bind 
indirectly to importin P via an adaptor protein: import of basic NLS-containing cargos 
is mediated by importin a  (Dingwall and Laskey, 1998), U snRNAs bind the Snurpoitin 
adaptor (Palacios et aL, 1997) and Replication protein A binds the RIPa adaptor 
(Jullien et aL, 1999). These receptors are generally large (90-130kDa) acidic proteins 
sharing 15-25% sequence identity. They all have an N-terminal RanGTP-binding 
domain, an N-terminal cargo-binding domain, and the capacity to bind components of 
the NPC. The genome of S.cerevisiae encodes nine receptors and one importin a  
adaptor (Corbett and Silver, 1997; Pemberton et aL, 1998; Wozniak et aL, 1998). In 
higher eukaryotes, similar numbers of import receptors have been identified but at least 
6 importin a  adaptor family members exist (Mattaj and Englmeier, 1998), including one 
member, hSRPly, which has been shown to be tissue specific (Nachury et aL, 1998).
1-2.3. Translocation across the nuclear membrane
Upon aiTival at the cytoplasmic face of the nuclear pore complex, the cargo- 
receptor complex docks through association with the FG-rich domains of nucleoporins 
(Ohno et aL, 1998). Although at present it is far from cleai’ how the complex travels the
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200nm length of the NPC, it has been suggested that repeated association and 
dissociation of the import cargo complex with nucleoporins may drive vectorial 
translocation across the NPC (Nakielny et aL, 1999).
Early studies identified nuclear import as a RanGTP hydrolysis-dependent 
translocation mechanism (Melchior et aL, 1993; Moore and Blobel, 1993) (Figure 1.6). 
RanGAPl and RanBPl cainy out activation of Ran’s GTPase activity, converting 
RanGTP to RanGDP in the cytoplasm. RanGDP will form a stable association with 
cargo-import receptor complexes in the cytoplasm (Hopper et aL, 1990; Matunis et aL, 
1996; Mahajan et aL, 1997). Ran’s major guanine nucleotide exchange factor is 
chromatin-bound RCCl, which generates RanGTP inside the nucleus. Release of the 
cargo from the NPC in the nucleus is triggered when RanGTP binds to the nuclear 
import receptor (Ohtsubo et aL, 1989; Bischoff and Ponstingl, 1991). The importance 
of the asymmetric distribution of RCCl and RanGAPl has been underscored by studies 
showing that inverting the gradient of Ran GTP across the nuclear membrane in vitro 
allows the direction of traffic to be reversed (Nachury and Weis, 1999). Although the 
vectorial nature of nuclear transport is dependent upon the RanGTP/GDP gradient 
(Gorlich et aL, 1996; Koepp et aL, 1996), the only step at which GTP hydrolysis is 
required for the nuclear transport cycle is at the end of a nuclear export event. Thus, it 
remains uncertain how the translocation event is powered (Koepp and Silver, 1996; 
Melchior and Gerace, 1998).
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Figure 1.6
Nudeocytoplasmic transport and the Ran cycle
Model for import and export o f receptor-cargo com plexes through the nuclear 
pore. In the cytoplasm, cargo associates with the receptor via its NLS and is translocated to 
the nucleus. RanGTP binding to an import receptor through the conserved ran binding 
domain dissociates the cargo-receptor complex in the nucleus. In the nucleus, cargo will bind 
to the ranOTP-export receptor com plex via its NES. Once this trimeric com plex has 
translocated through the nuclear pore, RanGAPl and RanBPl trigger GTP hydrolysis, thereby 
causing the release o f  the cargo from the export receptor.
1-2.4. Nuclear export
Studying the recycling of importin a  has provided novel insights into nuclear 
export mechanisms. After depositing their cargos in the nucleus, the import receptor 
shuttles back through the NPC, as a RanGTP-receptor complex. Export receptors bind 
cargo with much higher affinity in the presence of RanGTP (i.e., in conditions found in 
the nucleus) (Fornerod et ah, 1997; Kutay et aL, 1997; Arts et aL, 1998). The exportin 
CAS (originally identified as ‘cellular apoptosis susceptibility protein’ or Cselp in 
yeast) was identified as a RanGTP-dependent export factor for importin a  (Kutay et aL, 
1997). When this trimeric complex encounters RanGAP and RanBPl on the 
cytoplasmic side of the NPC, it disassembles, releasing the export cargo and the 
receptor in a form competent for binding NLS-bearing cargo (Rexach and Blobel, 1995; 
Gorlich et aL, 1996; Izuiralde and Adam, 1998; Hieda et aL, 1999). Following the 
exporting event, NFT2 protein binds to RanGDP in the cytoplasm and delivers Ran 
back into the nucleus to maintain the RanGTP gradient (Ribbeck et aL, 1998; Smith et 
aL, 1998) (Figure 1.6).
The majority of research in the nuclear export field has focused on the CRMl 
(exportin 1) pathway since the discovery of an antibiotic, leptomycin B, which has been 
shown to inhibit all CRMl dependent export from the nucleus (Wolff et aL, 1997; 
Fornerod et al 1997). CRMl is a receptor that functions in the export of a group of 
proteins that cairies a specific leucine-rich type of nuclear export signal (NES) by 
targeting them to nucleoporins within the NPC (Fornerod et al., 1997; Moroianu, 1998). 
The drug is now being used to identify other proteins that exit the nucleus via this 
pathway.
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1-2.5. Export of RNPs
The vast majority of cellular RNA molecules are synthesized in the nucleus 
therefore transportation to the cytoplasm is required before they can function in 
translation. All four major classes of RNA (mRNA, rRNA, U snRNA, and tRNA) are 
exported as large RNPs (Naldelny et aL, 1997). RNAs have complex NLSs, which 
become functional only when the RNP is fully processed. This ensures that non­
functional RNPs do not get into the cytoplasm. Each class of RNA uses preferred 
export factors as each type of RNA will block only its own export when present in 
excess (Jarmolowski et aL, 1994; Pokiywka and Goldfarb, 1995). Several export 
factors have now been discovered (Figurel.5). Independently, Arts et al (1998) and 
Kutay et al (1998) identified exportin-t, a specific RanGTP-bound factor responsible for 
directly exporting tRNA from the nucleus. Other RNPs require an adaptor protein: the 
binding of CBC (cap binding complex) adaptor to the 5’ m7G cap of U snRNA is 
required for its nuclear export by CRMl (IzauiTalde et aL, 1995; Fornerod et aL, 1997) 
and the heterogenous nuclear RNP (hnRNP) A1 protein, which commonly complexes 
with precursor and mature mRNAs, cames a NES within the M9 sequence to bridge 
mRNA to the CRMl export pathway (Michael et aL, 1995). Studying how retroviruses, 
such as human immunodeficiency virus (HIV), export their intron-containing RNA 
genomes and mRNA from the nucleus has uncovered many of the components of the 
cellular export machinery. Rev is a 13kDa viral NES-bearing RNA-binding protein that 
was originally identified as being involved in exporting HIV RNA out of the nucleus in 
a leptomycin B-sensitive pathway. Analysis of leptomycin B action lead to the 
discovery of the CRMl export factor (Fischer et aL, 1994; Wen et aL, 1995).
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Evidence exists to support the theory that import receptors and export receptor 
complexes make distinct contacts with nucleoporins, as some nucleoporin mutations 
specifically inhibit import or export (Corbett and Silver, 1997). It is unclear at present 
whether cai’gos move through an individual NPC in both directions at the same time, or 
if each NPC operates as a one-way system with only one entrance. It is also unknown 
what keeps the cargo moving in the right direction through the pore.
1-2.6. Regulating transport
A number of cellular processes are regulated at the level of nudeocytoplasmic 
transport. Controlling access to the nucleus is an efficient way to regulate the activity 
of proteins involved in transcription (Morehouse et aL, 1999) or DNA replication 
(Moore et aL, 1999). The physiological state of the cell dictates the rate of transport 
and the maximum aperture of the NPC (Feldhen* et aL, 1998). For example, passing 
from quiescence to proliferation to transfoi*mation increases both of these parameters. 
This may be a result of regulation of expression of transport receptors or changes in the 
Ran system. SV40 large T antigen has also been shown to cause an increase in the 
aperture of the NPC (Feldhen* et aL, 1994).
Highly specific regulatory mechanisms exist that affect the localisation of 
individual proteins in response to stimuli during the cell cycle (Ohno and Mattaj, 1999; 
Pines, 1999), in signalling pathways and during development (Hood and Silver, 1999) 
(Figure 1.7). Post-translational modification plays a major role in this regulation by 
altering the affinity of the cargo for transport receptors. For example, the yeast 
transcription factor Pho4p must be phosphorylated to be recognised by its export
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receptor and dephosphorylated to be recognised by its import receptor. Méthylation of 
arginine residues has also been found to have an effect on the export of some yeast 
hnRNP proteins (Shen et aL, 1998).
Alternatively, an associated factor may detenmne the cellular localisation of a 
protein. An accessory protein may hold a potential target in the cytoplasm by masldng 
a NLS/NES domain from the import/export machinery. Stimulation of translocation 
then involves dissociation of the complex and functional activation of the NLS/NES, 
generally by modification of either the signal-bearing protein or the accessory protein. 
For example, phosphorylation of the cytoplasmic retention factor iKb disrupts its 
interaction with the transcription factor NFkB, allowing the NLS of NFkB to be 
recognised by import receptors (Mattaj and Englemeier, 1998). On the other hand, an 
accessory protein may provide a signal, such as a NLS or a NES, to direct the protein 
into a specific compartment of the cell. For example, the cyclin component of 
Cdk2/cyclin E and Cdc2/cyclin B acts as a nuclear targeting subunit for its partner 
kinase. Cyclin E binds to the importin a  adaptor subunit while cyclin B l binds directly 
to importin (3, the cdk catalytic subunits are dispensable for these interactions (Moore et 
aL, 1999), As well as supplying a NLS, cyclin B l also provides a NES to an associated 
kinase (Hagting et aL, 1998; Yang et aL, 1998). Another example of an accessory 
protein providing a NES signal can be seen in regulation of p53.
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Figure 1.7
Regulated nuclear import/export
(A) P ost-translational modification: Phophorylation and méthylation play an 
important role in signalling proteins as targets for import to or export from the nucleus. 
R etention: A ccessory factors may mask an NLS/N ES to protect a protein from 
identification by the nudeocytoplasm ic transport machinery.
Piggyback transport: proteins may access the nudeocytoplasm ic tranport machinery 
th ro u g h  a s s o c ia t io n  w ith  an N L S /N E S -p o s s e s s in g  a c c e s s o r y  p ro te in .
In non-stressed cells, p53 associates with MDM2 and moves from the nucleus to 
the cytoplasm to be degraded by ubiquitin-mediated proteolysis (Haupt et aL, 1997; 
Kubbutat et al., 1997). In this situation MDM2 provides a NES for CRMl-dependent 
p53 export (Roth et aL, 1998). In response to DNA damage, DNA-PK (Shieh et aL, 
1997) and INK (Fuchs et aL, 1998) phosphorylate p53, decreasing its interaction with 
MDM2. This results in an increased accumulation of p53 in the nucleus where it carries 
out its roles in apoptotic death or cell cycle arrest. The tumour suppressor protein ARF 
has also been shown to inhibit the nuclear export of p53/MDM2 (Zhang et aL, 1999)
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1-3. 14-3-3 proteins
14-3-3 proteins were named after their migration pattern on two-dimensional 
DEAE-cellulose chromatography and starch electrophoresis during a search for small 
acidic proteins in the brain (Moore et aL, 1967). It is now known that 14-3-3 proteins 
are expressed in a broad range of tissues and cell types (Morrison, 1994) and increasing 
evidence has shown that 14-3-3 proteins possess diverse biochemical activities related 
to signal transduction, cell cycle regulation and apoptosis.
1-3.1. The 14-3-3 family of proteins
The 14-3-3 family of proteins comprise of nine highly homologous members in 
mammals i(a, (3, y, 5, e, q, a, t, and Q' derived from seven distinct genes (a  and Ô are 
phosphorylated forms of p and Ç respectively), and two to five members in plants, 
yeast, and fungi. 14-3-3 molecules are 30-33 kDa proteins that can form homo- and 
heterodimeric cup-shaped structures with two peptide-binding grooves aiTanged in an 
anti-parallel fashion, 30 Angstroms apart (Liu et aL, 1995; Xiao et aL, 1995; Petosa et 
aL, 1998). (Figure 1.8). Sequence alignment reveals five highly conserved sequence 
blocks. Blocks 2-5 correlate well with the alpha helices 3, 5, 7, and 9, which foiTn the 
proposed internal binding domain in the 3-dimensional-structure model of the 
functioning dimer (Wang and Shakes, 1996) (Figure 1.8). Supporting the current view 
that 14-3-3 proteins act as adaptor or bridging molecules that modulate interactions 
between components of signal transduction pathways, 14-3-3Ç has been shown to be
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Figure 1.8 
The 14-3-3 dimer
Schematic representation o f  the 14-3-3 dimer showing predicted position o f  
helices from interacting proteins in red. The central space is lined with highly conserved 
residues from helices 3, 5, 7 and 9 (shown in yellow and blue) which provide an invariant 
binding space for an amphipathic alpha helix, the specificity o f which being dictated by the 
less conserved surface loop regions.
capable of binding two different peptide motifs simultaneously, thereby inducing 
homodimer or heterodimer formation in its target proteins (Petosa et a l ,  1998). 14-3-3 
proteins have been shown to bind to discrete phosphoserine-containing motifs R - 
{S /Ay)  - [+] - pS - [LEAM] - P, present in many signalling molecules (Muslin et aL, 
1996; Yaffe et aL, 1997). Other motifs have been suggested to be important for binding 
of target proteins to 14-3-3 proteins, including a serine-rich patch on one side of an a- 
helix (Du et aL, 1996) or an amphipathic helix (Xiao et aL, 1995).
Although it has been reported that certain signalling proteins such as Cdc25A 
and B (Conklin et aL, 1995), Wee-1 (Honda et aL, 1997) and Raf (Freed et aL, 1994) 
interact with paiticulai’ 14-3-3 isotypes, the significance and regulatory role, if any, of 
these isotype-specific interactions is unclear. In contrast to these results, 14-3-3 
isotypes select almost identical phosphopeptide motifs from peptide libraries suggesting 
that perceived isotype binding-specificity arises not from inherent differences in ligand- 
binding ability, but from sub-cellular localisation, transcriptional regulation, post- 
translational modification or cell-specific abundance of particular isoforms (Yaffe ef aL, 
1997; Rittenger et aL, 1999). For example, the t  isotype is restricted to T-cells 
(Bonnef0 y-Berard et aL, 1995) and the Ô isotype is uniquely expressed in epithelial 
cells (Leffers et aL, 1993).
Interestingly, the 14-3-3 epsilon gene is found on chromosome 17pl3.3, which 
is within a region frequently deleted in several types of cancer, therefore pushing 14-3-3 
forward as a reasonable candidate tumour suppressor gene. Although many different 
biological activities have been attributed to 14-3-3 molecules (Figure 1.9), three 
pathways have been extensively researched lately (Figure 1.10).
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14-3-3 regulated signalling pathways
(A) 14-3-3 retains cdc25 in the cytoplasm. During interphase, or DNA damage, 
cdc25 can be phosphorylated by several kinases to create a 14-3-3 binding site. 14-3-3  
bound cdc25 is found in the cytoplasm  where it cannot act on cdc2, thus preventing 
mitosis. Phosphatases disrupt the cdc25-14-3-3 interation when mitosis is to be initiated, 
allowing the cdc25 phosphatase to enter the nucleus and activate cdc2. 14 -3 -3 a  may 
sequester the cdc2/cyclinBl complex in the cytoplasm in response to DNA damage.
(B) 14-3-3 sequesters Bad from mitochondrial Bc1-Xl/Bc1-2. Bad binds Bc1-Xl/  
Bcl-2 in the mitochondria, favouring apoptosis. Survival signals stimulate Akt/PKB 
leading to phosphorylation o f  Bad. Phosphorylated Bad is found in the cytosol and is 
unable to induce cell death. Akt/PK B also phosphorylates and inactivates other 
substrates in the pro-apoptotic pathway.
1-3.2. 14-3-3 in cell cycle regulation
During interphase, the activity of the mitotic inducer Cdc25C is suppressed as a 
result of binding to 14-3-3 proteins (Peng et a l,  1997; Kumagai et a l,  1998) (Figure 
LIO-A). This association is ultimately reversed at mitosis, unless the cell has damaged 
or unreplicated DNA, Release of the Cdc25C dual-specificity phosphatase activity at 
the G2/M boundary initiates activation of cyclin B/Cdc2 by removing inhibitory 
phosphates at Thr-14 and Tyr-15 (Dunphy and Kumagai 1991; Gautier et a l,  1991). 
The cyclin B/Cdc2 complex, also known as MPF (maturation or mitosis phase 
promoting factor) acts by phosphorylating a myriad of mitotic substrates that 
orchestrate the committed segregation of replicated chromosomes to daughter cells. 
MPF remains active until Weel and Mytl Idnases replace the inhibitory phosphates on 
Cdc2 at the metaphase-anaphase transition (Morgan, 1995).
The association of human Cdc25C with 14-3-3 has been shown to be promoted 
by phosphorylation of Cdc25C on Ser-216, which resides in a consensus 14-3-3 binding 
site, by Chkl, Cdsl and c-TAKl, although other kinases may also be involved (Furnari 
et a l,  1997; Peng et a l ,  1997; Sanchez et a l,  1997; Kumagai et a l ,  1998, Matsuoka et 
al,  1998).
The binding of 14-3-3 has little or no effect on the in vitro phosphatase activity 
of Cdc25C, suggesting that 14-3-3 proteins do not directly affect catalysis (Peng et a l, 
1997; Kumagai et a l,  1998; Blasina et al., 1999). This lead to the hypothesis that 14-3- 
3 acts to physically preclude the ability of Cdc25 to interact physically with the 
Cdc2/cyclin B complex. During interphase, Cdc25 is cytoplasmic, however, the active
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mitotic form of the phosphatase is nuclear. Abrogation of the 14-3-3 binding region on 
Cdc25 results in nuclear accumulation of Cdc25, demonstrating that 14-3-3 is 
responsible for the cytoplasmic localisation of Cdc25 during inteiphase. Several groups 
have results to explain this observation.
Studies of Xenopus Cdc25 have shown that the binding site for 14-3-3 is 
immediately adjacent to a putative bipartite nuclear localisation signal sequence, 
suggesting a mechanism whereby 14-3-3 proteins could influence the intracellular 
localisation of this regulatory phosphatase (Yang et al., 1999). In accordance with this, 
Dunphy and Kumagai have shown that the binding of 14-3-3 sterically inhibits the 
association of Cdc25 with importin a, implying a function for 14-3-3 in reversibly 
hindering the nuclear import of Cdc25. In this scenario, dissociation of 14-3-3 would 
result in nuclear translocation of Cdc25, and if conditions were appropriate for mitosis, 
Cdc25 would be activated by phosphorylation, by the polo Idnase Plxl, in the nuclear 
export signal of Cdc25 to prevent export of the phosphatase. Should conditions not be 
favourable for mitosis, then Cdc25 would remain phosphorylated only within the 14-3-3 
binding region and promptly be exported from the nucleus to rebind 14-3-3 in the 
cytoplasm.
In addition, studies in yeast by Lopez-Girona et al. (1999) have suggested that 
14-3-3, termed Rad24 in yeast, is actively exported from the nucleus via an inherent 
nuclear export signal. Mutation of this signal resulted in nuclear accumulation of 
Rad24 and also Cdc25, implying that Rad24 acts as a phosphorylation-dependent 
attachable NES for Cdc25. In agreement with these results, Rittenger et al (1999) have 
identified, by X-ray crystallography, a putative nucleai’ export signal located within the
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ligand-binding domain of 14-3-3. In the absence of bound ligand, 14-3-3 would be 
exported from the nucleus via Crml, the nuclear export receptor, however, in the 
presence of ligand, 14-3-3 would be prevented from interacting with Crml, leaving the 
compartmental fate of the complex dependent upon the availability of the NES from the 
other 14-3-3 subunit or from additional NES/NLS sequences within the bound ligand.
1-3.3. 14-3-3 in the DNA damage checkpoint
If DNA is damaged, a delay in the cell cycle facilitates repair. Cells respond to 
damage by stopping the cell cycle at either G l, before DNA replication, S phase in 
response to replication failures, or before chromosome segregation in G2 (Hartwell and 
Weinert, 1989). 14-3-3 proteins link the checkpoint pathway to the cell cycle
machinery to aid this arrest.
In epithelial cells, expression of 14-3-3(7 is induced in a p53-dependent manner 
in response to DNA damage and, when over-produced, 14-3-3(7 blocks the cell cycle at 
G2 (Hermeldng et a l,  1997). This is achieved by the promotion of cytoplasmic 
accumulation of Cdc2/cyclin B by 14-3-3(7 (Chan et al., 1999). In addition, Waterman 
et al (1998) have shown that a physical interaction exists between p53 and 14-3-3(7. 
Dephosphorylation of p53 occurs in response to DNA-damage, thus creating a 
consensus binding site for 14-3-3 proteins and leading to most (if not all) p53 becoming 
complexed with 14-3-3(7. Subsequently, this association increases the affinity of p53 
for sequence-specific DNA, possibly by inducing the formation of p53 tetramers.
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Moreover, DNA damage induced anest of the cell cycle can also be achieved in 
a p53-independent manner. Chkl/Cdsl Idnases, subsequent to activation by 
phosphorylation by the ATM  gene product or other as yet unknown Idnases, 
phosphorylate nuclear Cdc25C, creating a phosphoserine-binding site for 14-3-3 
proteins. This checkpoint operates to maintain Cdc25 in a 14-3-3- bound form rather 
than to induce 14-3-3 binding (Furnari et al., 1997; Peng et al., 1997; Sanchez et al., 
1997). This impedes nuclear accumulation of Cdc25C therefore preventing it from 
activating Cdc2 (Chan et al., 1999). Chen et al (1999) claim that the phosphorylated 
foim of Chkl, generated in response to DNA damage, also forms a direct complex with 
14-3-3, presumably to direct Chkl to a specific substrate or to a particular location 
within the cell.
Chan et al (1999) have shown that initiation of the checkpoint response does not 
require p53, but depends on the association of Cdc25C with 14-3-3 proteins. 
Maintenance of the checkpoint does however depend on p53 dependent expression of 
14-3-3(7 that subsequently causes the exclusion of cdc2 and cyclin B from the nucleus. 
The p53/14-3-3 association is not required to initiate the G2 arrest, but is critical for 
cells to sustain and perhaps recover from the delay.
These data present mechanisms for G2 arrest but it is conceivable that 14-3-3 
also plays a role in G l and S phase checkpoints through other checkpoint kinases and 
Cdks. AiTest in S phase, when DNA replication is blocked, may in some cell types also 
require Cdc2 phosphorylation (Peng et a l, 1997), but in some cases S phase an'est 
involves additional mechanisms unrelated to Cdk2 phosphorylation (Kumagai and 
Dunphy 1995; Lee et a l, 1996; Amon et a l,  1993). Arrest in G l, after DNA damage.
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is partly regulated by p21, an inhibitor of Cdk activity, and inhibitory phosphorylation 
of Cdk4 (Terada et al., 1995). Future work is expected to find a role for 14-3-3 proteins 
in these checkpoints too.
1-3.4. 14-3-3 in the apoptotlc response
Apoptosis is a naturally occuning cell death process that is critical for the 
development of multicellular organisms. The life or death decision made by cells is 
deteimined by sensitive balancing of the activities of survival and death promoting 
factors (Jacobson et al., 1997). Execution of apoptosis is ensured by a series of 
transcription-independent events that include the activation of cascades of caspases that 
results in cell disintegration followed by engulfment by sunounding cells (Steller et al., 
1995). Transcription-dependent events such as up regulation of p53, Bax, the Fas 
ligand and TNFoc are also part of the apoptotlc response pathway (Jacobson et al.,
1997). 14-3-3 proteins aie involved in the implementation of the cell death/survival 
choice.
The apoptosis-inducing molecule BAD contains two 14-3-3 binding sites. BAD 
is a member of the Bcl-2 family of proteins, which is comprised of positive and 
negative regulators of cell death. The ratio of antagonists (BCL-2, BCL-Xl, MCL-1, 
and A l) to agonists (BAX, BAK, BCL-Xs. and BAD) dictates whether a cell will 
respond to a proximal apoptotlc signal (Oltvai and Korsmeyer, 1994). BAD exerts its 
death-promoting effects by heterodimerising with, and neutralising the activity of, 
BCL-2 or BCL-Xl survival factors (Yang et al., 1995). In response to the survival 
factor IL-3, BAD becomes phosphorylated and forms an association with 14-3-3 in the
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cytoplasm. Sequestration of BAD protects it from phosphatases and prevents it from 
heterodimerising with the membrane associated BCL-Xl, and thus, protects the cell 
from undergoing apoptosis (Zha et a l, 1996).
Interestingly, one of the kinases responsible for phosphorylating BAD to create 
a 14-3-3 binding site, Akt (protein kinase B), also induces binding of the forkhead 
transcription factor FKHRLl to 14-3-3 (Brunet et a l,  1999). The Akt serine/threonine 
Idnase is a general mediator of cell survival, catalysing the phosphorylation, and 
therefore inactivation, of pro-apoptotic BAD and Caspase 9 (Datta et a l, 1997; Cardone 
et a l, 1998). In the presence of survival factors, Akt phosphorylates FKHRLl, leading 
to association with 14-3-3 proteins and retention of FKHRLl in the cytoplasm (Brunet 
et a l,  1999). Cytoplasmic retention and hence inactivation of FKHRLl function, 
suppresses the transcription of death genes such as the Fas ligand gene, and thereby 
promotes cell survival.
A downstream component of Fas-induced apoptosis, apoptosis signal-regulated 
kinase l(ASKl), is also subject to regulation by 14-3-3 proteins (Chang et a l, 1998). 
The death-promoting activity of ASKl is antagonised by its binding to 14-3-3 proteins. 
Although it is unknown how this is achieved, 14-3-3 does not affect the kinase activity 
of ASKl, therefore it is assumed that 14-3-3 acts to prevent interactions between ASKl 
and its death effectors (Zheng et a l, 1999).
These reports all indicate an apoptotic-suppressing role for 14-3-3, where 
several different components of the apoptotic response pathway are targeted in response
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to cell survival signals. This places 14-3-3 in a pivotal role in sustaining cellular 
growth.
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1-4. Ubiquitin-mediated proteolysis in cell cycle control
Regulation of cellular processes, including cell cycle progression, 
differentiation, and signal transduction, is mediated largely by modulation of steady 
state levels of key regulatory proteins (Koepp et al., 1999). This is achieved by 
regulating the level of protein synthesis and the level of degradation. The ubiquitin- 
proteasome pathway is responsible for the majority of specific cellular protein 
degradation. Degradation of a protein via the ubiquitin system involves two distinct 
and successive steps. Initially, the target proteins are conjugated to the polypeptide 
ubiquitin; in the second step, the ubiquitin-conjugated proteins aie accepted by the 26S 
proteasome, a large, multi-catalytic pro tease, and degraded (Kornitzer and Ciechanover, 
2000). Targets of the system comprise of not only soluble cytoplasmic and nuclear 
proteins, but also membrane-anchored proteins and lumenal endoplasmic reticulum 
(ER) proteins (Hicke, 1997). The discovery that tumor suppressor proteins such as p53 
(Scheffner et al., 1993; Ciechanover et al., 1991, 1994), transcriptional regulators and 
proto-oncogenes such as c-jun, c-fos (Stancovski et al., 1995; Treier et al., 1994; 
Tsurumi et al., 1995;), c-myc (Gross-Mesilaty et al., 1998; Salghetti et al., 2000), and 
P-catenin (Aberle et al., 1997; Jiang and Struhl, 1998; Kitagawa et a i,  1999; Orford et 
al., 1997; Winston et al., 1999), and cell cycle modulators such as the cyclin-dependent 
kinase (CDK) inhibitor p27 Kipl (CaiTano et al., 1999; Pagano et a l, 1995;) are 
targeted by the system has raised the possibility that aberrations in the process may 
result in human pathologies. Indeed, the accelerated degradation of p53 induced by the 
human papillomavirus oncogene product E6  in conjunction with E6 -AP has been 
implicated in the pathogenesis of human uterine cervical carcinoma (Scheffner et al.,
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1990, 1993). The levels of another tumor suppressor protein, the CDK inhibitor p27 
Kipl, are decreased in many types of malignancies, and this decrease was shown in 
some cases to be linked to increased degradation of the protein (Loda et al., 1997). The 
versatility of the ubiquitin-proteasome system derives from both its diversity and its 
specificity. Because cells possess a diverse collection of ubiquitinating enzymes, 
ubiquitin-mediated proteolysis targets a wide range of proteins for destruction. The 
main determinant of degradation by the proteasome is likely to be the level of 
ubiquitination of the substrate. Regulation at the level of ubiquitination could be 
achieved via several mechanisms: the activity of specific E2/E3 complexes toward 
certain substrates, or classes of substrates, could be modulated or the substrate could be 
modified to alter its affinity for the appropriate E3 complex.
1-4.1. The ubiquitination reaction
Ubiquitination involves the covalent conjugation of ubiquitin, a highly 
conserved, 76 amino acid residue protein, to a target protein via an isopeptide bond 
between the carboxyl-tenninus of ubiquitin and lysine e-amino groups of the target 
proteins (Breitschopf et al., 1998). The enzymatic machinery responsible for ubiquitin 
conjugation consists of at least two distinct catalytic entities, the ubiquitin activating 
enzyme (El) and the ubiquitin-carrier protein (or ubiquitin conjugating enzyme), E2 
(Hershko et al., 1983). Ubiquitin is initially conjugated in an ATP-requiring reaction to 
E l via a thioester bond between its C-terminal carboxyl group and a cysteine side chain 
in the active site of the enzyme. A /raus'-esterification reaction transfers the activated 
ubiquitin to a cysteine residue in the active site of the E2, which then transfers the 
ubiquitin to an amino group of the target protein. A third component, called E3, or
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ubiquitin-protein ligase, is responsible for substrate recognition; it serves to bring the 
E2 enzyme to the vicinity of the substrate and catalyze the transfer of ubiquitin from the 
thioester intermediate on E2 or E3 to an amide linkage with the substrate. A fourth 
component of the ubiquitin system, whose activity may be restricted to a specific and 
limited subset of E3/substrate combinations, has recently been proposed (Koegl et al., 
1999). E4 is a protein required for ubiquitin chain elongation: it binds to short ubiquitin 
chains, and in the presence of E l, E2, and E3, allows the formation of longer chains, 
which are recognized by the proteasome. In successive reactions, transfer of additional 
ubiquitin moieties to the e-amino group of Lys48 of the previous conjugated molecule 
produces a polyubiquitin chain that targets the substrate for degradation by the 
proteasome (Chau et al., 1989).
1-4.2. The E3 family
A member of the E3 family of proteins recognizes polyubiquitination signals, 
which may be primary, secondary or post-translationally modified sequences. Because 
E3s dictate the specificity of ubiquitination reactions, it is likely that protein 
degradation is substantially controlled via the regulation of E3 activity or the E3- 
substrate interaction. This family can be subdivided into at least four subtypes with 
regard to structure and/or class of degradation signal being recognised.
(i) E3a (UBRl in yeast) recognizes the destabilizing residues of N-end rule 
substrates (Bartel et a l, 1990; Hershko et al., 1986; Kwon et al., 1998). E3a has 
binding sites for either basic (type I) or bulky hydrophobic (type II) N-terminal residues 
of their substrates. However, E 3a has additional binding sites for other degradation
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signals as it can also recognize denatured and N-acetylated proteins. A protein related 
to E 3a has been identified, ESP, which targets proteins with small uncharged N- 
terminal residues for degradation (Heller and Hershko, 1990).
(ii) HECT (homologous to E6 -AP carboxyl terminus) domain proteins caiTy a 
350 amino acid residue domain homologous to the C-terminal domain of the 
prototypical member of the family, E6 -AP (Huibregtse et al., 1995). This domain 
contains a conserved cysteine residue for attachment of a ubiquitin molecule before it is 
transferred to the substrate (Scheffner et al., 1995). E6 -AP was identified as a protein 
required for the rapid degradation of the tumor suppressor p53 in the presence of 
papilloma virus protein E6  (Huibregtse et a l, 1993). E6 -AP is also the protein mutated 
in a human genetic disease, Angelman’s syndrome. Other members of this family 
include yeast RSP5, which conjugates RNA polymerase II (Huibregtse et a l, 1997) and 
NEDD4, which targets the kidney epithelial sodium channel (Staub et a l, 1997).
(iii) The anaphase promoting complex (APC) (Imiger et a l,  1995; King et al., 
1995) or cyclosome (Sudakin et a l, 1995) is a multi-protein complex of at least 10 
subunits, which has a ubiquitin-ligase activity specific for degradation of mitotic 
cyclins, anaphase inhibitors and spindle-associated proteins. Ancillary factors that are 
not part of the core complex confer further substrate specificity and regulation to the 
complex. Phosphorylation also appears to play a role in regulation of this complex 
(Shteinberg et a l, 1999). APC substrates contain a degradation signal called the mitotic 
‘destruction box’, with the following consensus sequence: R-A/T-A-L-G-X-I/V-G/T-N 
(conserved residues are in bold) (Yamano et a l, 1996).
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(iv) SCF complexes (^kpl, Cdc53 or Cullin, and F-box protein) are involved in 
the degradation of certain cell cycle regulators, such as the E2F-1, SICl CDK inhibitor, 
and certain G l cyclins. They associate with a specific E2, Cdc34/Ubc3 (Feldman et al., 
1997; Skowyra et al., 1997), and possibly also with the UbcH5 family of E2s (Yaron et 
a l, 1998; Gonen et a l, 1999). Recently, a fourth component of the SCF complex was 
identified, Rbxl (Kamura et a l, 1999; Skowyra et a l, 1999), or R o d  (Ohta et a l, 
1999; Tan et a l, 1999). Although both yeast and mammals contain additional cullin 
homologs, only CULl seems to associate with Skpl (Lisztwan et a l,  1998). Recently it 
was reported that CUL-3 targets cyclin E for degradation, but other components of this 
ubiquitination complex are unknown (Singer et a l, 1999). In contrast, the F-box 
protein is a variable component of the complex. Given that SCF complexes, with 
different F-box components, exhibit different substrate specificities, the F-box proteins 
are thought to caixy the substrate recognition site of the complex (Bai et a l,  1996). 
CULl recruits the E2 enzyme and Skpl helps to link the F-box/substrate with the E2 
enzyme. With the exception of SCF^ '^^  ^ (the superscript denotes the identity of the F 
box subunit), no specific consensus degradation signal has been recognized so far 
among the substrates of specific SCF complexes. However, a requirement for 
phosphorylation of the substrate before recognition by the SCF complex appears to be 
common to all SCF-substrate interactions.
1-4.3. The proteasome
The proteasome is a large, ~2.1MDa, 26S multi-catalytic protease that 
recognizes, binds, unfolds and degrades polyubiquitinated proteins into short peptides, 4 
to 25 residues long (Kisselev et a l, 1999). The 26S proteasome complex is composed
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of the 20S core catalytic complex flanked on both sides by the two regulatory 19S 
complexes (Baumeister et al., 1998). Crystal structure of the yeast 20S particle reveals 
a baiTel-shaped structure with catalytic sites located in the (3-rings in the interior of the 
baiTel, shielded from the cytoplasm (Groll et al., 1997). Electron microscopy shows 
that each extremity of the banel is capped by a 19S particle. The exact number of 19S 
complex subunits is unknown as some may only associate transiently with the 20S 
proteasome. One function of the 19S complex is presumably to recognize ubiquitinated 
proteins and other potential substrates of the proteasome. S5a (RpnlO/Mcbl in yeast) 
has been identified as a ubiquitin-binding subunit of the 19S particle (Deveraux et a l,
1994). The yeast 20S particle seems to be occluded at both ends (Groll et al., 1997), 
thus a second function of the 19S complex may be to change the conformation of the 
20S particle to create a channel through which substrates can be inserted into the 
proteolytic interior chamber. Many of the 19S subunits are ATPases (Voges et al., 
1999).
1-4.4. Regulation of ubiquitination activity.
Recent data regarding degradation of mitotic substrates by the APC shows that 
regulated degradation of specific classes of substrates can be achieved by modulating 
the activity of the ubiquitination machinery. This is achieved through the cell cycle 
dependent association of ancillary factors with the APC. Protein degradation by the 
APC is required for progression through anaphase (Irniger et al., 1995; Tugendreich et 
al., 1995) and the association of different ancillary proteins to the core APC complex 
prompts target specificity. Cut2 (in S.pombe) and Pdsl (in S. cerevisiae) (Funabiki et 
a i, 1996; Cohen-Fix et a l, 1996), APC substrates that act as inhibitors of the
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metaphase to anaphase transition, are degraded by the APC at the beginning of 
anaphase. Binding of the ancillary protein Cdc20 to the APC results in degradation of 
Pdsl, and binding of phosphorylated Hctl/Cdhl during telophase is required for 
degradation of cyclin B, as well as other late mitotic substrates such as Asel (Schwab et 
a l, 1997; Visintin et a l,  1997). In cases of spindle assembly failure, inactivation of 
Cdc20 through binding to Mad proteins will result in mitotic arrest (Fang et a l, 1998; 
Hwang et a l, 1998). Throughout most of the cell cycle, CDK-phosphorylation of 
H ctl/Cdhl renders it incapable of binding to the APC, therby preventing degradation of 
cyclin B (Jaspersen et a l,  1999; Zachariae et a l, 1998; Lukas et al 1999).
1-4.5. Regulation by modification of the substrate.
Post-translational modification of a substrate can regulate its ubiquitination by 
altering its binding affinity for an E3 enzyme. An increasing number of substrates of 
the ubiquitin pathway are known to require phosphorylation prior to ubiquitination, for 
example, the yeast G l cyclins Cln2 (Lanker et a l, 1996) and Cln3 (Yaglom et a l,
1995), the yeast cyclin-dependent Idnase (CDK) inhibitors Sicl (Verma et a l, 1997) 
and FaiT (Henchoz et a l, 1997), the mammalian G l cyclins D (Diehl et a l, 1997) and 
E (Clurman et a l, 1996), the mammalian CDK inhibitor p27 Kipl (Carrano et a l, 
1999; Sheaff et a l, 1997; Tsvetkov et a l, 1999), and the mammalian transcriptional 
regulators iKBa (Brown et a l, 1995; Yaron et a l, 1997) and (3-catenin (Rubinfeld et 
a l, 1997). Interestingly, the E3 enzymes that associate with substrates regulated by 
phosphorylation ai’e all members of the SCF family of ligases. Two of the best- 
characterised cases are those of IkB œ and Sicl degradation.
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The mammalian transcription factor NF-kB is activated by a variety of 
extracellular stimuli such as tumor necrosis factor, cytokines, bacterial and viral 
products, and ionizing inadiation (Ghosh et ah, 1998; Mercurio and Manning, 1999). 
Activation is achieved when iKBa, which binds to NFkB and sequesters it in the 
cytoplasm, is degraded, thus allowing NFkB to translocate to the nucleus. 
Phosphorylation of NF-i<JB-bound iKBa on its N-terminal regulatory domain, at two 
specific serine residues, serines 32 and 36, triggers the polyubiquitination of nearby 
lysines. The subsequent proteasomal degradation of iKBa follows association with a 
specific SCF complex, SCF^^‘^ ''(Fuchs et ah, 1999; Kroll et ah, 1999; Spencer et al., 
1999; Winston et al., 1999; Yaron et ah, 1998). Another substrate of SCF*^ '^^ '’, the 
transcription factor P-catenin, is phosphorylated by a distinct kinase, glycogen synthase 
kinase (GSK3a), on two serines embedded in a sequence similar to the Ser 32 -Ser 36 
region of IkBu (Fuchs et al., 1999; Hart et ah, 1999; Latres et al., 1999). A consensus 
recognition motif has been identified for pTrCP binding: D S'’ G L X S*’ (single-letter 
amino acid code; S'* stands for phosphoserine). However, no consensus recognition 
motif has been defined yet for other F-box proteins.
Sicl is a yeast cyclin B/CDK complex inhibitor whose rapid degradation at the 
end of G l enables the initiation of DNA replication (Schwob et al., 1994). Cell cycle 
regulated phosphorylation of Sicl by G l cyclin/CDK complexes is critical for the 
recognition of Sicl by the SCF ubiquitination complex (Feldman et a l, 1997).
In addition to phosphorylation of the substrate, ubiquitination of an SCF 
substrate could conceivably be modulated by the presence or absence of the specific F-
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box protein. The mammalian CDK inhibitor p27, and the transcription factor E2F-1, 
are ubiquitinated by a specific SCF complex, SCF (Caixano et al., 1999; Marti et al., 
1999; Tsvetkov et a l,  1999). Skp2 activity is essential for S-phase entry, and Skp2 
expression is itself cell cycle regulated, with a peak of expression during S phase 
(Zhang et al., 1995). The association of F box proteins with Skpl can also be regulated 
(Li and Johnston, 1997).
Inhibition of ubiquitination by phosphorylation has also been described. 
Ubiquitin-mediated degradation of the proto-oncogene c-mos is inhibited by 
phosphorylation on Ser3 (Nishizawa et a l, 1992; Nishizawa et a l, 1993). Interestingly, 
activation of c-mos leads to phosphorylation and stabilization of c-fos, another substrate 
of the ubiquitin pathway (Okazald and Sagata, 1995). Another example is that of the 
anti-apoptotic protein Bcl-2: dephosphorylation of Bcl-2 following apoptotic stimuli 
renders it susceptible to degradation by the ubiquitin pathway (Dimmeler et al., 1999).
1-4.6. Regulation by binding of viral factors.
Certain viruses are capable of manipulating the cellular ubiquitination system to 
target cellular substrates that may obstruct propagation of the virus. In some instances, 
the viral protein functions as a bridging protein between the E3 ligase and the substrate. 
The prototype of such an interaction is the HECT protein, E6 -AP (F<5-Associated 
Protein). It was isolated as a protein required for the ubiquitination of p53 in the 
presence of the human papillomavirus (HPV) oncoprotein E6 . E6  binds both p53 and 
E6 -AP, and formation of this complex results in the ubiquitination and degradation of 
p53 (Huibregtse et a l, 1991). Removal of the tumour suppressor by the oncoprotein
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appears to be a major mechanism utilised by the virus to transform cells. The T-cell 
CD4 receptor is another example of an endogenous substrate that is targeted for 
degradation by a viral protein. The Vpu protein of the human immunodeficiency virus 
type 1 (HIV-1) binds to the CD4 receptor of the T cells infected by the virus, leading to 
ubiquitination and degradation of CD4 by the complex (Margottin et al., 1998).
1-4.7. Regulation by masking of a degradation signal.
Incorporation of a protein into a complex may protect it from degradation. 
Cyclin E is protected from ubiquitination when assembled with Cdk2 (Clurman et al.,
1996) and E2F-1 is protected from ubiquitination when assembled with pRB (Hoffmann 
et al., 1996). The a2  transcription factor in budding yeast is also regulated in this way. 
When two haploid yeast cells of opposite mating types mate, the resulting diploid 
expresses both al and a2, which form a heterodimer with a distinct DNA binding 
specificity. In haploid cells, the al and a2 proteins are rapidly degraded by the 
ubiquitin system. It was shown that residues that are important for the interaction with 
al overlap with the Degl degradation signal (Johnson et al., 1998). Thus, binding of al 
interferes with the recognition of a 2  by the ubiquitin system because of masking of the 
degradation signal. Another example was recently shown where the Drosophila 
homeobox protein Homothorax is stabilized in cells expressing its binding partner 
Extradenticle (Abu-Shaar and Mann, 1998). On the other hand, binding to DNA can 
stabilize a DNA-binding protein. The myogenic transcription factor MyoD can be 
efficiently ubiquitinated in vitro', however, binding of MyoD to its specific cognate 
DNA sequence protects it from ubiquitin-mediated degradation (Abu Hatoum et al..
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1998). Furthermore, Salghetti et al., (2000) propose that an overlap of acidic activation 
domains and destruction elements in certain transcription factors, presents a mechanism 
for destruction of excess activators, thereby preventing squelching of the basal 
transcription machinery.
1-4.8. Deubiquitination.
Deubiquitinating enzymes (DUBs) can either accelerate or inhibit proteolysis. 
This process is essential for the release of newly synthesized ubiquitin, which is often 
translated as a linear polyubiquitin molecule, or fused to a ribosomal protein. 
Following proteolysis of a conjugated substrate, recycling of the ubiquitin molecules by 
deubiquitinating enzymes is also essential to restore the cellular ubiquitin pool. In 
addition, deubiquitination has the potential of inhibiting ubiquitin-mediated proteolysis 
by releasing ubiquitin chains from substrates before they reach the proteasome. This 
may serve as a proofread facility to prevent degradation of substrates that were falsely 
ubiquitinated.
The ubiquitin recycling enzymes are generally thiol proteases that recognize the 
C-terminal domain of ubiquitin (Wilkinson, 1997). Ubiquitin C-terminal hydrolases 
(UCHs) are ~25kDa enzymes that are involved in the processing of pro-ubiquitin 
products. Ubiquitin-specific proteases (UBPs) are -lOOldDa enzymes that catalyze the 
release of ubiquitin from polyubiquitin chains or from conjugated cellulai' proteins. 
These enzyme families have been shown to target specific substrates. UBP3 has a role 
in inhibiting gene silencing of transcribed genes following positioning near 
heterochromatic regions (Moazed and Johnson, 1996). DUB-1 and DUB-2 are induced
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by cytokines, and high-level expression of DUB-1 leads to cell cycle aiTest (Zhu et al., 
1996, 1997).
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1-5. Objectives
Progress in elucidating the molecular composition of E2F has defined a 
heterodimeric transcription factor composed of an E2F and a DP family member. To 
date, six E2F proteins and at least three DP proteins have been identified, and each E2F 
protein can interact combinatorially with a DP protein to generate an array of sequence 
specific heterodimers (Dyson 1998). Although it is known that the E2F family 
members perform a physiological role in dictating the nature of the pocket protein that 
physically interacts with the heterodimer, little is known about the functional 
differences between heterodimers comprising different DP partners.
With a view towards understanding the physiological role of the DP subunit of 
the E2F heterodimer, this project firstly focused on a putative nuclear localisation signal 
present only in certain members of the DP family. An alternatively spliced bipartite 
nuclear localisation signal was uncovered and a role for this splicing event in E2F 
function was analysed.
Of particular interest was the C-terminal portion (basic region) of the nuclear 
localisation signal, which was, unlike the N-terminal portion, present in all the DP 
family members. The next stage of the project aimed to define a role for this region by 
assuming it was associated with an interaction domain within the DP protein. It was 
subsequently found to mediate an interaction between the E2F transcription factor and 
the epsilon isofoim of the 14-3-3 family of signalling molecules.
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Finally, the project aimed to propose a functional role for 14-3-3 in the E2F 
pathway. With the aid of a mutant DP, which failed to bind to 14-3-3, functional 
analysis revealed a role for 14-3-3 in mediating cell cycle progression by promoting the 
degradation of E2F in the G2 phase of the cell cycle. This suggested a link between the 
E2F transcription pathway and a growth regulating pathway, possibly through a 02- 
phase checkpoint monitor.
In considering the role of the DP protein, it is noteworthy that DP-1 appears to 
be the predominant DP family member in physiological E2F (Bandara et ah, 1993, 
1994; Girling et aL, 1993). It is possible that DP-3 proteins aie rare components of E2F 
or alternatively, regulate E2F site-dependent transcription in physiological conditions 
where DP-1 does not play a major role. Another possibility is that DP-3 proteins are 
down-regulated in tumour cells, a theory which is in keeping with the results of this 
study. Understanding the nature of the different DP proteins will ultimately 
discriminate between the various roles of the E2F family members and consequently, 
yield important insights into cell cycle control.
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Chapter 2. Materials and methods
2-1.1. Plasmids
The following plasmids have been previously described; pCMV-pl07 
(Beijersbergen et aL, 1994), pCMV-HA-E2F-5 (Allen et aL, 1997), pCMVHA-E2F-4 
(Beijersbergen et aL, 1994), pCMV-jBgal (Zamanian et aL, 1992), pGDP-3(3, pGDP-30 
(de la Luna et aL, 1996), pGDP-1 (Bandara et aL, 1993), pCE-luc ( Botz et al 1996), 
pG5Elb-luc (Lee et aL, 1998), pVP 16-TAD (Lee et aL, 1998), pG4DP-36 (de la Luna 
et aL, 1999), pG4DP-l (de la Luna et aL, 1999), pG4-DBD (de la Luna et aL, 1999), 
pVP16-LEU (Shikama et a l, 1999), pfflS-LEX-DBD (Buck et a l,  1995), pBSK-DP-3 
(Ormondroyd et aL, 1995), pT7ElA (Allen et aL, 1997), pSG5 (Green et aL, 1988)
The following plasmids were gratefully received as gifts: pRcCMVHA-E2F-l 
encoding E2F-1 (Krek et aL, 1994) from Dr W, Krek, pCMV-14-3-3e-myc, encoding 
14-3-3 e, and pGEX-14-3-38, encoding GST tagged 14-3-3s, from Dr A. Aitken.
pGDP-3ôAb was constructed by adopting the PGR method to delete 18bp from 
pGDP-35 (bases 174-191 inclusive). The first PGR was canned out using the 5' primer 
(5' to 3') TGGGGGGGGATGATTATAAGGAGA and the 3' primer (5' to 3') 
GGGATTTTTATGAGTTTGTGAGAA (encompassing the deletion). The second PGR 
was carried out using the 5' primer (5' to 3') TTGTGAGAAAGTGATAAAAATGGG 
(encompassing the deletion) and the 3' primer (5’ to 3') 
GAAGTTGTTGTAGGTGGGGTG. The final PGR used the products of PGR 1 and
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PCR 2 with the 5' primer of PCR 1 and the 3' primer of PCR 2. PCR amplification was 
carried out using Taq polymerase (Promega) for PCR 1 and PCR 2, as this enzyme did 
not digest overhangs of the primer after the first round of annealing. PCR 3 was 
performed using Pfu polymerase (Boehringer Mannheim), as this enzyme has higher 
fidelity in amplification. PCR was carried out using the manufacturer's incubation 
buffer for 31 cycles as follows: 5 minutes dénaturation at 94°C, followed by 31 cycles 
of dénaturation at 94°C for 30 seconds; annealing at 45°C for 30 seconds; extension at 
72°C for 30 seconds (last cycle 5 min). The PCR product was digested with Smal and 
Bell and sub-cloned into pBSKDP-35 that had been digested with Smal and Bell to 
remove wild-type DP-3 sequence initially. For expression in mammalian cells, the DP- 
3 sequence was sub-cloned into pG4mpolyII (Stratagene) in place of the GAL4 DNA 
binding domain sequence.
pG4DP-3pAb was constructed as pG4DP-3ôAb using the following primers: 
PCR 1- 5’ primer (5* to 3') TCCCCGGGGATGATTATAAGCACA and the 3' primer (5' 
to 3') CCCATTTTTATCACTGGGAACCC (encompassing the deletion). PCR 2- 5' 
primer (5' to 3') GGGTTCCC AGTG AT A A A A ATGGG (encompassing the deletion) 
and the 3' primer (5' to 3’) GAAGTTCTTGTAGCTGGGCTC.
For the mammalian two-hybrid assay, pVP16TADl4-3-3e was constructed by 
amplifying pCMV-14-3-3e-myc by PCR using the 5' primer (5' to 3') 
GGCATTACGGCAATTCATGGATGATCGGGG and the 3' primer (5’ to 3’) 
CGCATGCCATGGATCCCAAGTCCTCTTCAG that created digestion sites for EcoRI 
and BamHI. PCR amplification was earned out using Pfu polymerase (Boehringer 
Mannheim) and the manufacturer's incubation buffer for 31 cycles as follows: 5minutes
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dénaturation at 94°C, followed by 31 cycles of dénaturation at 94°C for 30 seconds; 
annealing at 70°C for 30 seconds; extension at 72°C for 30 seconds (last cycle 5 min). 
The PCR product was digested with EcoRI and BamHI and sub-cloned into the vector 
pCMVHA-VP16TAD which had been digested with BamHI and EcoRI to excise the 
HA tag.
To construct pHL-DP36 M2 E and pHL-DP3dM^EAb for the yeast two-hybrid
assay, pG4-DP35 (bases 1-388) or pG4-DP3ôAb* (bases 1-370) was amplified by PCR 
using the 5' primer (5' to 3') TCCCCGGGGATGATTATAAGCACA and the 3' primer 
(5’ to 3’) CATCATAAACTCTTCCGTCTA. PCR amplification was earned out using 
Pfu polymerase (Boehringer Mannheim) and the manufacturer's incubation buffer for 31 
cycles as follows: 5 minutes dénaturation at 94°C, followed by 31 cycles of 
dénaturation at 94°C for 30 seconds; annealing at 50°C for 30 seconds; extension at 
72°C for 30 seconds (last cycle 5 min). The PCR product was digested with Smal- 
PvuII and sub-cloned into the vector pHIS-LEXA linearised by Smal.
The predicted DNA sequence of all constructs was verified by DNA sequencing 
both strands manually (Sequenase, Amersham) or with an ABI dye terminator cycle 
sequencing-ready reaction kit (Perkin Elmer) and an automated DNA sequence 
analyser.
2-1.2. Luciferase and p-galactosidase reporter assays
For luciferase assay, cells were washed twice with PBS before lysing in 300|il 
reporter lysis buffer (25mM Tris-H3P04 pH7.8, 2mM 1,2-diaminocyclohexane tetra
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acetic acid, 2mM DTT, 10% glycerol and 1% Triton X-100) for 30 minutes. The lysed 
cells were then transferred to a micro centrifuge tube and spun to remove cell debris. 
To assay for luciferase activity lOOpl cell extract was added to 300ja.l luciferase assay 
reagent (1:4, Promega) and luciferase activity measured using a luminometer (Berthold 
Lumat).
To measure P-galactosidase activity, lOOpl cell extract was incubated with 2 x 
P-gal substrate buffer (200mM sodium phosphate buffer pH 7.3, 2mM MgCl^, lOOmM 
p-mercaptoethanol and 1.33mg/ml O-nitrophenyl-P-D-galactopyranoside). The 
reaction mixtures were incubated at 37°C until faintly yellow in colour and the enzyme 
activity was quantified by measuring the optical density of the mixture at a light 
wavelength of 420nm.
2-1.3. Immunofluorescence
Transfected cells were fixed in 4% paraformaldehyde at room temperature for 
15min, washed in PBS, then permeabilised in PBS containing 0.2% Triton X-100 for 
lOmin. Fixed cells were then washed three times with PBS-1% PCS and incubated in 
primary antibody diluted in PBS-5% FCS for 30min. After washing again in PBS-1% 
FCS, cells were incubated in secondary antibody; goat anti-mouse or anti-rabbit IgG 
conjugated to fluorescein isothiocyanate (FITC) or tetramethyl rhodamine 
isothiocyanate (TRITC) (Southern Biotechnology Associates Inc.) diluted in PBS-10% 
FCS for 30min at room temperature. Finally, coverslips were washed three times in
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PBS, mounted on slides using citifluor (Citifluor Ltd), and viewed using a fluorescence 
microscope (Olympus).
2-1.4, Flow cytometry
For flow cytometry analysis, lOpg of an expression vector for the cell-surface 
protein CD20 was co-transfected into cells (grown in 10% FCS) together with 4pg of 
each expression vector of E2F and DP. Cells were washed and fresh full media added 
after 16h then harvested 24h later by washing in PBS and thereafter treating with cell 
dissociation medium (Sigma) for 30min at 37°C. Cells were washed in DMEM by 
centrifugation at lOOOrpm for 3min and resuspended in 200fxl DMEM containing 20|il 
anti-CD20 antibody leu 16 (Becton Dickinson) coupled to fluorescein isothiocyanate 
(FITC). Cells were incubated on ice for 20min then washed twice with PBS, Finally, 
cells were fixed by adding 50% PBS in ethanol drop wise and storing at 4°C overnight. 
Cells were collected by centrifugation and resuspended in 400jil propidium iodide 
(20pg/ml) in PBS and 200(il RNase (125U/ml) in PBS and incubated on ice for 30min, 
Flow cytometry was performed on a Becton Dickinson fluorescence activated cell 
sorter. Using CellQuest software, the cell cycle profile of the transfected population of 
cells (at least lO'^  cells per sample) was determined by analysing the intensity of 
propidium iodide staining in cell populations that were positive for FITC staining. The 
data presented show a representative example from multiple assays.
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2-1.5. Transfection
For transfection, U20S, COS-7 and CV-1 cells were maintained in Dulbecco’s 
modified eagles medium (DMEM) supplemented with 10% foetal calf serum (FCS) and 
antibiotics, lOmg/ml streptomycin and lOOU/ml penicillin (Gibco BRL), at 37°C in a 
5% CO2  / H2 Ü-saturated atmosphere. Cells were plated out 24hr before transfection at
~2 X 10^  cells per 35mm dish (on coverslips for immunofluorescence), ~5 x 10^ cells 
per 60mm dish (for luciferase and p-galactosidase assays) or -1.5 x 10^ cells per 
100mm dish (for immunoprécipitation, stability and flow cytometric analyses). Three 
hours before the transfection, the medium from the cells was removed and replaced with 
fresh growth medium.
Transfection of U20S cells was earned out using the calcium phosphate-DNA 
precipitate method: A 250mM CaC12 solution (lOOpl per 35mm dish, 250pl per 60mm 
dish and 750pl per 100mm) containing either 6 jig (p35), 15|Lig (p60) or 56|ag (p i00) 
plasmid DNA.
For immunostaining assays (p35), 2|Lig of each plasmid DNA was used. 
Transactivation assays (p60) used 0.5jLig reporter, 0.5|ag pCMVp-gal, 0.5pg DP and 
E2F and 2jig 14-3-3 plasmid. Immunoblotting, immunoprécipitation and gel shift 
assays (p i00) used lOjXg each of DP and E2F and 4jig pCMVP-gal with empty vector 
maintaining the final DNA amount constant.
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DNA/CaClj solution was added drop wise to an equal volume of 2xHBS 
solution (50mM HEPES pH7.1, 280mM NaCl, and 1.5mM Na2HP04) and left 20 min 
to precipitate before adding to media on cells.
4|il Lipofectin Reagent (Gibco) was used to transfect COS-7 and CV-1 cells, I 
according to manufacturer’s instructions, with 6 jtg DNA per 35mm dish.
Whenever required, pcDNA3 (Invitrogen) or pSG5 was used to maintain a 
constant amount of DNA in each sample. All transfections included pCMV-pgal 
(Invitrogen) as an internal control for transfection efficiency. Cells were washed 3x 
with PBS 14-17 hr post transfection. For stability analysis, 100mm dishes were 
trypsinised at this point into 4 x 60mm dishes to maintain equal transfection efficiency 
levels between samples. U20S cells were haiwested 40-46hrs post-transfection and 
COS-7 and CV-1 cells were hai'vested 64-7Ohrs post- transfection.
2-1.6. Immunoprécipitation
Cells were washed twice in PBS, hai'vested by scraping into cold Lysis Buffer 
(20mM HEPES pH7.5, 400mM NaCl, ImM EDTA, 0.1% NP-40, lOmM NaF, 2.5mM 
DTT, 0.5mM PMSF, l.OmM sodium orthovanedate and aprotinin (2.0pg/ml)) and 
incubated on ice for 30min. The cell extract was centifuged for 15 min at 12,000g then 
diluted in Lysis Buffer without NaCl to give a final salt concentration of 150mM. The 
extract was pre-cleared by incubating with protein-G agarose for Ih at 4°C in a vibrax 
machine. The supernatant was harvested and incubated with 50|Ltl protein-A agarose
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(50% v/v) (Boehringer Mannheim) for 2h at 4°C. The protein-A agarose had been 
previously incubated with primary antibody in lOOpl incubation buffer (20mM HEPES 
pH7.5, 150mM NaCl, ImM EDTA, 0.1% NP-40, for Ih at room temperature. The 
agarose beads were collected by centrifugation for 30sec at 5,000g, the supernatant 
removed and the pellet washed three times in incubation buffer. Bound proteins were 
released into 2xSDS loading buffer (250mM Tris-HCl, pH6 .8 , 20% glycerol (v/v), 4% 
SDS (w/v), 0.1% bromophenol blue (w/v), 200mM DTT and 5% P-mercaptoethanol). 
The denatured sample was electrophoresed in a 10% SDS-polyacrylamide gel and 
Western blotted.
2-1.7. Western Blotting
To measure the levels of protein expression in cells, extracts were immobilized 
on nitrocellulose membranes (Inverclyde Biochemicals Ltd), blocked in PBS-10% milk 
for 20min then incubated with primary antibody. As secondary antibody in 
immunoblotting, the blots were incubated with either alkaline phosphatase-conjugated 
goat anti-rabbit or -mouse IgG (1:5,000, Promega), or horseradish peroxidase- 
conjugated goat anti-rabbit or -mouse IgG (1:4,000) for ECL (Amersham) as 
recommended by the manufacturer.
2-1.8. GST recombinant protein purification
TransfoiTned BL21 bacteria were grown to mid-logarithmic stage in LB-broth 
before protein expression was induced by the addition of ImM (final concentration)
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isopropyl-P-D-thiogalactopyranoside (IPTG) and incubated for 4hr at 30°C. Bacterial 
pellets were resuspended in 10ml PBS/1 % Triton X-100 and 0.5mM PMSF on ice, and 
then sonicated briefly (3 x lOsec) on ice. Bacterial debris was pelletted by 
centrifugation and re-centrifugation at 10,000rpm for 15min (at 4°C) each. 300p.l of 
glutathione-agarose beads (33% v/v) in suspension (0.05% NaN3 in PBS) was added to 
the supernatant and mixed with constant rotation at 4°C for 30min. The suspension was 
washed twice with 50ml PBS by spinning in a bench-top centrifuge at 5,000rpm for 
5min (at 4°C). The washed beads were stored in PBS-azide at 4°C for up to one week. 
Protein expression was measured by coomassie after SDS-PAGE.
2-1.9. In vitro binding assay
For the in vitro binding reactions, approximately lOjug of GST or GST-fusion 
protein bound to glutathione-agarose beads was added to extract from transfected COS- 
7 cells (as described above). After incubation for 2hr at 4°C, the beads were collected 
and washed four times in incubation buffer (see 2-1.6.). Proteins were released into 
SDS-sample buffer, electrophoresed, and detected by immunoblotting.
2-1.10. Yeast two-hybrid Assay
Yeast strain
Saccharomyces cerevisiae CTY10.5d with integrated plasmid pSH18-34. This 
plasmid carries 4 binding sites for LexA upstream of the transcription start site of a 
lacZ gene. Genotype is MATa ade2 trp 1-901 leu2-3,112 his3-200 gal4 gal80 
URA3::lexA op4acZ
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cDNA library
10.5 d.p.c CD-I mouse embryo library generaterd by random-primed cDNA 
synthesis and size selected to have insert sizes in the range 350-700 nucleotides cloned 
into vector pVP16, which canies the LEU2 gene, to create a VP 16-library fusion 
protein.
Bait
DP-35 residues 1-110 cloned into vector pLexA that carries the HIS3 gene to 
create a LexA-bait fusion protein.
Assay
Yeast was transformed simultaneously with bait and library plasmid using the 
lithium acetate method (based on method of Ito et aL, 1983). Approximately 2x10^ 
transformants were seeded on 16 x 140mm dishes containing synthetic medium lacking 
leucine and histidine. Colonies were assayed for P-galactosidase activity by filter 
assay. Blue colonies were isolated and cured of bait plasmid by growing to saturation 
in selective liquid media in the presence of histidine. After replica plating on selelctive 
minimal agar, plasmid DNA from Trp+His' colonies that failed to give a blue colour 
when assayed for*P-galactosidase were recovered into Eschericia coli XL 1-blue strain. 
PCR using vectors from the library backbone vector verified that library plasmid was 
successfully isolated. A plasmid conferring a Ti-p+ phenotype that gave a blue colony 
colour only in the presence of bait was selected and DNA sequenced on both strands 
with an ABI dye terminator cycle sequencing-ready reaction Idt (Perkin Elmer) and an 
automated DNA sequence analyser. Sequences were assembled into contigs with the
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Seqman programme from the DNAStar package (DNASTAR, Inc.). Database seai'ches 
and sequence comparisons were done using the BLAST (Altschul et aL, 1990), gapped 
BLAST and PSI-BLAST (Altschul et aL, 1997) programs provided by the National 
Center for Biotechnology Information (NCBI).
2-1.11. Gel retardation assay
The binding sequence for E2F derived from the adenovirus (ad5) E2a promoter 
from -71 to -50, 5’-GATCTAGTTTTCGCGCTTAAATTTGA-3' and 3'-
ATCAAAAGCGCGAATTTAAACTCTAG-5', was radiolabelled with 32p_(%_GTP 
(Amersham). Approximately 4|ug of U20S or COS-7 cell extract (prepared as above) 
was used for each gel shift reaction and made up to a final volume of 20|Li1 with reaction 
buffer (4x; 200mM Tris-HCl pH7.9, 24mM MgC12, 0.8mM EDTA, 4mM DTT and 
60% glycerol (v/v)), 2pg of sonicated-salmon sperm DNA (Sigma) and 200ng of 
mutant promoter oligo; 5-GATCTAGTTTTCGATATTAAATTTGA-3' and 3- 
ATCAAAAGCTATAATTTAAACTCTAG-5' to remove the non-specific DNA 
binding activity. The mixture was incubated for lOmin at room temperature before 
adding 6ng of 32p_Q^_QYP-labelled oligonucleotide probe for a further lOmin 
incubation at room temperature. Reaction mixtures were loaded on to a non-denaturing 
4% polyacrylamide Tris-borate EDTA (TAE) gel at 4°C and ran at 250V for 2h.
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2-1.12. Protein stability assay
Transfection was canied out as above. For half-life measurements, cells were 
incubated withlOmg/ml cyclohexamide (Promega) freshly prepared in ethanol. At time 
points thereafter, dishes were washed twice with PBS before harvesting in SDS sample 
buffer.
To inhibit ubiquitin-proteasome mediated degradation, two hours before 
harvesting, cells were incubated with 50mM A-acetyl-L-leucinyl-L-leucinyl-N- 
norleucinal (LLnL) (Promega) in DMSO or as a control, DMSO only.
2-1.13. In vitro protein expression
In vitro transcription and translation was earned out using a TNT T7 coupled 
reticulocyte lysate system (Promega) as recommended by manufacturer, in the presence 
of 35S methionine. To check expression Ipl was used in SDS-PAGE and 
autoradiographed. lOpl was used for each immunoprécipitation reaction.
2-1.14. Single-site in vitro mutagenesis
DP-3Ô target for mutagenesis was produced as anti-sense single stranded DNA 
by cloning into the M13K07 vector. In vitro mutagenesis was carried out using the 
Sculptor kit (Amersham) using the following oligonucleotides to introduce single site 
mutations into DP-35 DNA:
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DP-3ôS„A (5’ to 3’) GAGACATTTTTGCAATGAAGGTG 
DP-3ÔS,,A (5’ to 3’) GAAAGTAAACGAGCCAAAAAAGGAG
The predicted DNA sequence of both constructs was verified by DNA 
sequencing both strands manually (Sequenase, Amersham) or with an ABI dye 
terminator cycle sequencing-ready reaction kit (Perkin Elmer) and an automated DNA 
sequence analyser.
2-1.15. Antibodies
Primary
DP-3
DP-1
HA
pl07
T7
E2F-1
14-3-3
myc
rabbit polyclonal serum raised against sequence common to all DP-3s
rabbit polyclonal antiserun 098 raised against a C-terminal peptide
mouse monoclonal H A ll (BabCO)
mouse monoclonal SD9 (SantaCruz)
mouse monoclonal (BabCO)
rabbit polyclonal KH95 (Santa Cruz)
rabbit polyclonal cross reactive with all 14-3-3 isoforms (Santa Cruz) 
mouse monoclonal 9E10 (Santa Cruz)
Secondary
Anti-Ig-TRITC
Anti-Ig-FITC
Anti-Ig-hip
Anti-Ig-AP
Anti-CD20-FITC
rhodamine conjugated (Southern Biotechnology Associates, Inc) 
fluorescein conjugated (Southern Biotechnology Associates, Inc 
horseradish peroxidase conjugated (Amersham)
Alkaline phosphatase conjugated (Promega) 
fluorescein conjugated (Becton Dickinson)
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Chapter 3. Nuclear accumulation of E2F is 
regulated by heterodimerisation
3-1. Introduction
The recent isolation of a novel member of the DP family, DP-3 (Ormondroyd et 
ah, 1995), provided a valuable tool to advance the understanding of the functional 
regulation of E2F. DP-3 RNA undergoes extensive processing events to generate 
distinct DP-3 proteins, four of which have been isolated (de la Luna et aL, 1996). A 
sequence of 16 amino acid residues, known as the E region, is one such region subject 
to alternative splicing (Ormondroyd et aL, 1995) and discovery of this uncovered a 
significant splicing event that occurs throughout the DP family (Figure 3.1-A). Given 
that the sizes of the E2F and DP families are ever expanding, it is becoming more likely 
that heterodimers may not be functionally redundant.
This chapter aimed to define the functional significance of the E region by 
comparing properties of the E+ and E- members of the DP family and by studying the 
influence these proteins had on a heterodimeric E2F transcription factor. It had 
previously been shown that the DP proteins that possess the E region required a higher 
salt concentration to extract the protein from transfected COS-7 cells than was required 
for extraction of E- DP proteins (de la Luna et aL, 1996). As low salt conditions release 
mostly cytoplasmic proteins, higher salt conditions being required to release nuclear 
proteins with the cytoplasmic proteins, these results suggested that the different
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Figure 3.1
M embers o f  the DP fam ily  have d ist in ct  su h -ce llu lar  loca lisa t ion
(A) Diagrammatic representation o f  the DP family illustrating the conserved  
domain m ediating DNA binding/dim érisation (in blue) and the E region (in red).
(B) The intracellular distribution o f  exogenously expressed DP-1 (i), DP-3fl (ii) 
and DP-3Ô (iii) protein was assessed by immunofluorescence using rabbit anti-peptide 
serum 7.2 (DP-3) or 098 (DP-1).
biochemical extraction properties reflected distinct intracellular distributions of the DP- 
3 proteins. This was investigated using indirect immunofluorescence of transfected 
cells to show the cellular localisation of DP and E2F, and did indeed reveal that the 
choice of heterodimeric partner was significant in controlling E2F activity by regulating 
intracellular location. Pocket proteins and viral oncoproteins, which have preferential 
specificity for particular E2Fs (Sardet et aL, 1997), also had an impact on the cellular 
localisation of E2F.
3-2. Results
3-2.1. The E-region contributes to the nuclear accumulation of DP
The intracellular distribution of the DP-3 proteins was determined by indirect 
immunfluorescence of transiently transfected COS-7 cells using either an anti-DP-3 
anti-serum, called 7.2, or an anti-DP-1 anti serum, called 098, both of which only 
recognise exogenous DP protein (primary antibodies failed to detect any DP protein in 
non-transfected cells). Results showed that the DP family can be sub-divided into two ' 
categories: those containing an E region, DP-3a and DP-35 (Figure 3.1-A) showed 
• nuclear accumulation (Figure 3.1-Biii), whereas those lacking the E region, DP-1 and 
DP-3p (Figure 3.1-A) were distributed throughout the cytoplasm (Figure 3.1-Bi and 
ii). Control experiments where perfoimed to ensure specificity of secondary 
antibodies (results not shown). These data establish that differences in protein 
sequence, i.e. the presence or absence of the E region, influenced the ability of the DP 
to efficiently accumulate in the nucleus.
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3-2.2. E2F proteins differ in their cellular distribution
To address the location of E2F protein, haemagglutinin (HA)-tagged E2F-1, -4, 
and ~5 were expressed, by transient transfection, in COS-7 cells and their location 
determined by indirect immunofluorescence. In these conditions, E2F-1 was found 
exclusively in the nucleus (Figure 3.2-Bi). In contrast, the majority of E2F-4 and E2F- 
5 transfected cells exhibited staining throughout the cytoplasm with a small number of 
cells showing nuclear staining also (Figure 3.2-Bii and iii). E2F-1 possesses an 
intrinsic nuclear localization signal (NTS) in the N-terminus of the protein (Krek et a l, 
1994), a region that is absent from E2F-4 and E2F-5 (Figure 3.2-A). These results 
support the hypothesis that the E2F family can be divided into two functional 
subgroups, as suggested from their primary sequence and functional properties (Buck et 
a l, 1995; Krek et al., 1994; Lukas et a l, 1996; Mann and Jones, 1996).
3-2.3. E2Fs devoid of an NES rely on heterodimerisation for translocation.
Although DP I was observed to be a cytoplasmic protein, it may not be actively 
retained in the cytoplasm as attachment of a foreign NLS caused nuclear accumulation 
(de la Luna et a l, 1996). Considering this, a possible mechanism for nuclear 
accumulation of a cytoplasmic DP could be through heterodimerisation with an NLS 
containing E2F partner. To test this idea, both HA-tagged E2F-1 and a cytoplasmic DP 
(DP-1 in figure 3.3-i and -ii or DP-3p in figure 3.3-iii and -iv) were co-expressed and 
their intracellular distribution determined by double immunostaining with anti-HA 
monoclonal antibody for E2F-1 and a polyclonal antibody for DP (Neither the 
rhodamine-conjugated anti-mouse immunoglobulin or fluorescein-conjugated anti-
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Figure 3.2
M embers o f  the E2F fam ily  have d istinct su h -ce llu lar  loca lisa tion
(A) Digrammatic representation o f  the E2F family, illustrating the conserved  
domains mediating cyclin A binding (in red), DNA binding/dimerisation (in blue) and 
trans-activation/pocket protein binding (in green).
(B) The intracellular distribution o f  exogenously expressed HA-tagged E2F-1 (i), 
E2F-4 (ii) and E2F-5 (iii) protein was assesed by immunofluorescence using an anti-HA 
monoclonal antibody 12CA5.
rabbit immunoglobulin cross-reacted with the anti-DP polyclonal or anti-HA 
monoclonal antibody (data not shown)). There was a striking difference in the 
distribution of DP-1 and DP-3p upon co-expression of E2F-1. Cells expressing the 
E2F-1 protein contained nuclear DP-1 (Figure 3.3-ii), in contrast to its cytoplasmic 
location in the absence of E2F-1 (Figure 3.1-i). Similar results were observed in the 
nuclear recruitment of DP-3P by E2F-1 (Figure 3.3-iv compared to its location in the 
absence of E2F-1 shown in figure 3.1-ii). These data strongly suggest that upon 
forming a DP/E2F-1 heterodimer, E2F-1 has a dominant influence on recruiting DP to a 
nuclear location. As shown in figure 3.2-Bii and iii, E2F can exist in a cytoplasmic 
foiTn too, so it was reasoned that heterodimerisation with an NLS-containing DP may 
influence its cellular location. Indeed, when co-expressed in COS-7 cells, double 
immunostaining with anti-HA monoclonal antibody for E2F-4 (Figure 3,4-i) or E2F-5 
(Figure 3.4-iii) and a polyclonal antibody for DP-35 (Figure 3.4-ii and iv) showed that 
the non-NES-containing E2F now accumulated efficiently in the nucleus. Note that in 
figure 3.4-i, one cell, indicated by an arrow, showed cytoplasmic E2F-4 due to the 
absence of a co-expressed DP-35 in this cell. These data indicated that the cytoplasmic 
location of E2F-4 and E2F-5 was likely to be passive since it could be overcome upon 
interaction with an NLS containing DP partner, defining a dominant role for the DP 
partner in the context of this heterodimer in regulating the nuclear accumulation of E2F.
3-2.4. Sub-cellular localization of E2F is affected by co-expression of pl07
E2F species are known to complex with pocket proteins (Bagchi et al., 1991; 
Bandara and La Thangue, 1991; Chellappan et aL, 1991; Chittenden et al., 1991; Gao et
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Figure 3.3
Nuclear E2F can m ediate nuclear translocation of a cytoplasm ic DP
The intracellular distribution o f  exogenously expressed DP and HA-tagged E2F 
partner, in cells expressing both proteins, was detected by immunofluorescence using a 
rabbit p o lyc lonal anti-D P-1 antibody ( ii) , anti-D P-3 antibody (iv ), and m ouse  
monoclonal anti-HA antibody (i) and (iii). Cells were co-transfected with HA-E2F-1 and 
either DP-1 (i) and ( i i)  or D P-3P ( i i i )  and (iv ). N ote that DP-1 exp ressin g  
cells that are not co-transfected with H A -E 2F-l(ii, the cell on the right) are not located 
to the nucleus.
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Figure 3.4
N uclear DP can m ediate nuclear translocation  o f  cytop lasm ic E2F
The intracellular distribution o f  exogenously expressed DP and HA-tagged E2F 
partner, in cells expressing both proteins, was detected by immunofluorescence using a 
rabbit polyclonal anti-DP-3 antibody (ii and iv) and mouse monoclonal anti-HA antibody 
(i and iii). Cells were co-transfected with DP-3Ô and either HA-E2F-4 (i and ii) or 
H A -E 2F -5  ( i i i  and iv ). An Arrow in d ica tes  c e ll  ex o g e n o u s ly  ex p re ss in g  
HA-E2F-4 alone.
a l, 1992; Devoto et a l, 1992; Shirodkar et a l, 1992; Cobrinik et a l, 1993). The 
cytoplasmic E2Fs -4  and -5  specifically interact with p i07 (Sardet et a l, 1997), which 
is a nuclear protein (Figure 3.5-i). To study whether association of pl07 with a 
cytoplasmic heterodimer could result in a nuclear E2F complex, U20S cells were co­
transfected with either HA-E2F-4 or -5  together with DP-3 (3 or DP-1, and the pocket 
protein pl07. Consistent with the absence of NLS activity in each protein, the 
heterodimer expressed without pl07 was cytoplasmic, as determined by double 
immunostaining with anti-HA monoclonal antibody for E2F-4 or -5 and a polyclonal 
antibody for DP-3p or DP-1 (Figure 3.5-ii, iii, vi and vii) Upon addition of pl07, both 
components of the heterodimer were observed to be strongly nuclear (Figure 3.5-iv, v, 
viii and ix). The nucleai* accumulation was dependent upon the expression of E2F since 
pl07 could not mediate nuclear translocation of DP-3(3 in cells not expressing an E2F 
(data not shown). These data suggest that the NLS of p i07, supplied to the heterodimer 
in trans, is essential for E2F nuclear translocation under the conditions used.
3-2.5. E2F, transported by pl07 into the nucleus, remains nuclear even after 
dissociation from pl07
It is known that the E2F/pl07 complex is a target of viral oncoproteins, such as 
Adenovirus E l a and SV40 large T antigen, resulting in release of E2F enabling cell 
cycle progression to ensue (Nevins, 1992). It was therefore of interest to determine the 
effect of viral oncoproteins on pl07-mediated nuclear translocation of E2F. The co­
expression of pl07 with E2F-4/DP-3(3 resulted in nuclear accumulation of DP-3 (Figure 
3.6-i and ii). Expression of E l a, at levels known to be sufficient to disrupt the
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Figure 3.5
Pocket proteins can mediate the nuclear accumulation of cytoplasmic  
E2F heterodimers
The intracellular distribution o f  exogenously expressed p i 07 (i), DP-3P and 
HA-E2F-4 (ii and iii), DP-3P and HA-E2F-4 co-expressed with p l0 7  (iv and v), DP-1 
and HA-E2F-5 (vi and vii) or DP-1 and F1A-E2F-5 co-expressed with p i 07 (viii and ix) 
was detected by im m unofluorescence using a rabbit polyclonal anti-D P -1 antibody 
(vii and ix) or anti-DP-3 (iii and v) or mouse monoclonal anti-HA antibody (i, iv, vi and 
viii) or anti p i07 antibody (i).
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Figure 3.6
Pocket protein-m ediated nuclear translocation of E2F is unaffected by 
adenovirus Ela
The intracellular distribution o f  exogenously co-expressed DP-3 (3, HA-E2F-4 and 
p l0 7  (i and ii) or DP-3(3, F1A-E2F-4, p l0 7  co-expressed with E la  (iii and iv) was detected 
by im m unofluorescence using a rabbit polyclonal anti-DP-3 antibody (ii and iv) and 
m ouse monoclonal anti-p l07  antibody (i and iii). Distribution o f  T7 tagged- E la  was 
assessed with a cytoplasm ic heterodimer (v and vi) and with a heterodimer expressed  
with p l0 7  (vii and v iii) using a m onoclonal anti-T7 antibody and rabbit polyclonal 
anti-DP-3 antibody. E la  alone is also shown (xi).
interaction between pl07 and E2F, did not affect this nuclear accumulation (Figure 3.6- 
iii and iv). E la  itself is a nuclear protein (Figure 3.6-xi) but cannot transport E2F-4/DP- 
3p to the nucleus (Figure 3.6-v and vi). When expressed with the heterodimer and p i07, 
E la  co-localised to the nucleus with DP-3P (Figure 3.6-vii and viii). Thus, the release 
of E2F from pocket protein sequestration does not alter the sub-cellular distribution of 
the E2F heterodimer, suggesting that the pocket protein release occurs once the 
E2F/pocket protein complex has entered the nucleus. There is also a suggestion here 
that the E2F heterodimer can be retained in the nucleus after the link with the 
transporter, pl07, has been disrupted.
3-3. Conclusion
It is known that physiological E2F arises when a member of each of two 
families of proteins, E2F and DP, interact as E2F/DP heterodimers capable of binding 
specific sequences of DNA and that transcriptional activity is regulated through 
physical association with pocket proteins. This chapter showed that these known 
features all regulate another aspect of E2F activity; that is, in controlling the levels of 
functional nucleai" E2F. For nuclear activity, either the DP or the E2F partner must 
provide an NLS. In the occasion where both partners are devoid of such a signal, 
association with a pocket protein will transport the heterodimer into the nucleus. In this 
case, the heterodimer will be expected to exist in a transcriptionally repressed state. 
However, should the pocket protein complex be disrupted, by CDKs or viral 
oncoproteins for example, an active nuclear E2F may be released.
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Chapter 4. The hasic region of DP is necessary for 
efficient nuclear accumulation of E2F 
heterodimers
4-1. Introduction
The observation that the E region is necessary for nuclear accumulation of DP 
suggests that it may function as, or contribute to, a nuclear localization signal. The 
process of alternative splicing of a nuclear localization signal was an exciting and 
unexpected mechanism uncovered for controlling E2F activity. It was of great interest 
therefore, to study the DNA sequence of this area in all the DPs (Figure 4.1).
Active transport of proteins into the nucleus is dependent upon short amino acid 
sequences composed of a high proportion of positively charged residues. An NLS may 
be a single-cluster, exemplified by SV40 T antigen, or bi-parti te, as in nucleoplasmin 
(Dingwall and Laskey, 1991). Single-cluster sites are defined as comprising at least 
four arginine and lysine residues, bi-partite motifs consist of two basic amino acids, a 
spacer region of any ten amino acids, then a basic cluster in which three out of the next 
five residues must be basic. Figure 4.1 shows that, by sequence alignment, both types 
of NLS consensus can be identified around the E region.
As sequence analysis revealed two putative NLSs, the aim of this chapter was to 
determine whether the E region contained a single-cluster SV40 Tag-like NLS or
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Figure 4.1
DPs contain a bipartite nuclear localisation signal
D iagram m atic representation o f  the DP fam ily o f  proteins illustrating the 
conservation o f  the nuclear localisation signal which is composed o f  the E region and the 
basic region. The N LSs o f  nucleoplasm in and SV40 T antigen are also shown for 
comparison. Similar and identical residues are indicated. The basic region deleted mutants, 
DP3-PAb and DP3-0Ab are also shown.
contributed to a bipartite NLS. An NLS is defined as a sequence necessary for nuclear 
targeting of the protein and it must be sufficient to direct a non-nuclear protein to the 
nucleus. The previous chapter demonstrated that the E region complies with the first 
statement. Although the putative NLS sequence within the E region bears resemblance 
to the SV40 T antigen NLS, it is not sufficient by itself to target a protein to the nucleus 
(de la Luna et al., 1996). However, the addition of a further eight residues C-terminal 
to the E region was sufficient to transfer a nuclear phenotype onto a non-nuclear 
protein. This implies that the E region does not contain an autonomous NLS but may 
function co-operatively with an additional sequence at the C terminal boundary of the E 
region. Insertion of the E region by alternative splicing may create a bi-partite NLS. 
To investigate this, the N-terminal basic cluster of the putative bipartite NLS was 
deleted and the phenotype of the resulting mutant DP characterised.
4-2. Results
4-2.1, The basic region is necessary for nuclear accumulation of E2F
To prove that the basic region forms part of the NLS in DP, DP-3Ô was mutated 
using PCR to excise DNA bases encoding six amino acids from the basic region. This 
protein was named DP~3ôAb (Figure 4.1). When expressed in COS-7 cells, wild type 
DP-3Ô was located in the nucleus, but the basic region-deleted protein failed to 
accumulate in the nucleus.
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Figure 4.2
The basic region is necessary for nuclear accumulation of E2F
(A ) The intracellular distribution o f  exogenously  expressed  D P-36 (i) or 
DP-36Ab (ii), detected by im m unofluorescence using a polyclonal anti-DP-3 peptide 
antibody.
(B) H A-E2F-4 co-expressed  with D P-36 (i and ii) or DP-36Ab (iii and iv) 
detected by im munofluorescence using a polyclonal anti-DP-3 peptide antibody (ii and 
iv) and a monoclonal anti-HA antibody (i and iii).
(C) H A-E2F-5 co-expressed  with D P-36 (i and ii) or DP-36Ab (iii and iv) 
detected by immunofluorescence using a polyclonal anti-DP-3 peptide antibody (ii and iv) 
and a monoclonal anti-HA antibody (i and iii)
The DP-3ÔAb protein was more abundant, paiticularly around the nuclear 
membrane, giving a “cauliflower-like” staining pattern (Figure 4.2-A, compare i with 
ii). As expected, DP-35 transported non-NLS-containing E2F-4 and E2F-5 into the 
nucleus (Figure 4.2-Bi and ii and 4.2-Ci and ii). Both the E region and the basic region 
were required for this function since DP-3ôAb was unable to transport E2F-4 and -5 into 
the nucleus (Figure 4.2-B and 4.2-C, compare i and ii with iii and iv). The staining 
results do show however, that E2F-4 and -5 co-localised with DP-35Ab in the cytoplasm 
as the particularly distinctive cauliflower-like pattern was transfeiTed to the E2F protein.
4-2.2. Heterodimerisation fails to efficiently transport DP-35Ab into the 
nucleus.
Co-expression of wild type DP-35 with E2F-1 in COS-7 cells resulted in nuclear 
co-localisation (Figure 4.3-Ai and ii). If DP-35Ab was co-expressed with E2F-1, one 
would expect E2F-1 to supply the NLS, and both proteins to translocate to the nucleus, 
as is the case for E2F-l/DP-3(3 heterodimers. However, only 50% of cells expressing 
both proteins exogenously, showed nucleai' co-localisation. The remaining 50% 
double-stained cells show nuclear accumulation of E2F-1, and DP-30Ab remaining in 
the cytoplasm (Figure 4.3-Aiii and iv). As the COS-7 cell line is transformed with 
SV40 large T antigen, these transfections were also earned out in the parental cell line 
CV-1. The results here implicated T antigen in the observations made in COS-7 cells 
since CV-1 (and also U20S) cells showed co-localisation of E2F-1 and DP-35Ab in the 
nueleus of all double-stained cells (Figure 4.3-Av and vi). This implies that under 
specific circumstances, the basic region is either involved in nuclear retention of the DP
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Figure 4.3
C o-expression of  nuclear E2F is not su ffic ient to m ediate nuclear  
translocation of basic deletion mutant DP
(A) The intracellular distribution o f exogenous HA tagged E2F-1 co-expressed 
with DP-3Ô (i and ii), or DP-3ôAb (iii, iv, v and vi), detected by immunofluorescence 
using a polyclonal anti-DP-3 peptide antibody (ii, iv and vi) and a monoclonal anti-HA 
antibody (i, iii, and v) in either COS-7 cells (i, ii, iii and iv) or CV-1 cells (v and vi)
(B) HA-E2F-4 and DP-30Ab (i and ii), co-expressed with p l0 7  (iii and iv) 
detected by immunofluorescence using a polyclonal anti-DP-3 peptide antibody (ii and 
iv) and a monoclonal anti-HA antibody (i and iii).
component, or nuclear export inhibition of DP after transport via E2F-1, or in regulating 
heterodimerisation in the cytoplasm, a phenotype that is only apparent in the presence 
of T antigen. As shown previously in figure 4.2-B, DP-35 can provide nuclear 
translocation to E2F-4 but DP-35Ab was unable to do this. Co-expression of the pocket 
protein pl07 did however, transport the heterodimer to the nucleus in all cells double 
stained for E2F and DP (Figure 4.3-B, compare i and ii with iii and iv); a role it 
performs with all non-NLS containing heterodimers. Removal of the basic region did 
not affect the pocket protein-mediated pathway into the nucleus.
4-2.3. Cytoplasmic DPs require an intact basic region for nuclear transport
Although cytoplasmic DPs do not contain the E region, the basic region is 
conserved throughout the DP family. To assess the role of the basic region in 
cytoplasmic DPs, DP-3p was mutated by PCR to excise DNA bases encoding six amino 
acids from the basic region. This protein was named DP-S^Ab (Figure 4.1). When co­
expressed in COS-7 cells, wild-type DP-3p was cytoplasmic (Figure 4.4-Ai), however 
immunostaining of the basic region-depleted-DP-3 p protein showed the protein to be 
absolutely excluded from the nucleus (Figure 4.4-Aii). Around 80% of DP-3p- 
expressing cells show the protein to be predominantly cytoplasmic with a low level of 
expression in the nucleus, presumably transported by endogenous E2F/pocket proteins, 
however, DP-SPAb stained cells show no nuclear staining whatsoever. Reminiscent of 
DP-35Ab stained cells, some of the DP-3PAb-expressing cells showed a cauliflower­
like staining pattern around the nuclear membrane, the DP-SPAb protein expression 
appeared more abundant than the wild type protein and more cells appeared to express
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The basic region o f  cytoplasm ic DPs is still necessary for e ff ic ien t  
nuclear accumulation of the heterodimer
(A ) The intracellular distribution o f  exogenous DP-3P (i) and DP-3pAb (ii) 
detected  by im m unofluorescence using a polyclonal anti-DP-3 peptide antibody.
(B) Sub-cellular distribution o f  wt and mutant DP-3|3 co-expressed with an E2F 
partner. HA-E2F-1 (i, ii, iii and iv) co-expressed with wt DP-3P (i and ii) or mutant 
DP-3P (iii and iv), and HA-E2F-5 co-expressed with DP-3pAb (v and vi) were detected 
by im m unofluorescence using a polyclonal anti-DP-3 peptide antibody (ii, iv and vi) 
or a m onoclonal anti-H A  antibody (i, iii and v). C ells indicated by an arrow 
show co-localisation o f  E2F and DP.
the mutant protein. As shown previously, HA-E2F-1 can transport DP-3P into the 
nucleus, however, when co-expressed with DP-3pAh, only 50% of co-transfected cells 
showed co-localisation in the nucleus (Figure 4.4-Biii and iv cells identified by arrows). 
The remaining 50% exhibited nuclear E2F-1 but DP-3PAb remained in the cytoplasm 
(Figure 4.4-B compare i and ii with iii and iv). It appears that the basic region in DP is 
necessary for efficient nuclear accumulation, and hence functional activity, of the E2F 
transcription factor, even if the DP does not possess the E region part of the NLS. As 
expected, DP-3pAb co-localises with HA-E2F-5 in the cytoplasm (Figure 4.4-B v and 
vi).
4-2.4. The DP basic region is not involved in heterodimerisation or DNA 
binding
It is deal' that the basic region has an important role to play in regulating E2F 
activity so it was essential to establish whether the mutant affects E2F 
heterodimerisation, which would subsequently affect Rb-binding, DNA binding, and 
transcriptional properties (Bandara et a l, 1993; 1994; Helin et al., 1993; Ki*ek et al., 
1993). To test heterodimerisation capabilities of the basic deletion mutant DP-3, DP- 
35, DP-35Ab, E2F-1 and E2F-5 proteins were in vitro transcribed and translated and 
immunoprécipitation experiments performed (Figure 4.5-A, lanes 1-8 show the relative 
expression of E2F and/or DP in the lysates used in the immunoprécipitations in lanes 9- 
16). Results showed that both DP-35 and DP-35Ab were immunoprecipitated equally 
well with the anti-DP-3 antibody (Figure 4.5-A, lanes 9 and 10).
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Figure 4.5
The basic region of DP-3Ô is not involved in the heterodimerisation of DP 
with E2F-1 or E2F-5
(A) Immunoprécipitation o f  HA-tagged E2F-5 and DP-3 from 35S-labelled in 
vitro translated rabbit reticulocyte lysates using a polyclonal anti-DP-3 peptide antibody, 
and proteins detected by autoradiography. The postitions o f  the labelled proteins are 
shown. Note the absence o f  E2F bands in the immunopreciptates not containing DP 
protein (lanes 11 and 14) showing no cross-reactivity occurs between the anti-DP-3 
antibody and the HA-tagged E2Fs.
(B) Immunoprécipitation o f  HA-tagged E2F-5 and DP-3 from transfected cell 
extracts using a polyclonal anti-DP-3 peptide antibody, and proteins detected by 
im m unoblotting  w ith the anti-H A  antibody 12CA 5. The p osition  o f  the co- 
immunoprecipitated E2F-5 bands are shown. Asterisks indicate the positions o f  the two 
hyper-phosphorylated E2F species.
E2F-1 and E2F-5 were both recovered efficiently in anti-DP-3 immunoprecipitates from 
lysates containing DP-35 or DP-35Ab suggesting that stable complexes of each DP-3 
formed with E2F-1 (Figure 4.5-A, lanes 15 and 16), and E2F-5 (Figure 4.5-A, lanes 12 
and 13) even when the basic region was deleted. E2F-1 and -5 were not present in anti- 
DP-3 immunoprecipitates when DP-3 was omitted from the reaction (Figure 4.5-A 
lanes 11 and 14). Thus, DP-35Ab can form stable complexes with E2F-1 and -5 in 
vitro.
Next, the association was tested in vivo. Figure 4.5-B shows that after transient 
transfection of HA-tagged E2F-5 and either DP-35 or DP-35Ab into U20S cells, HA- 
E2F-5 was detected in anti-DP-3 immunoprecipitates from both extracts (Figure 4.5-B, 
lanes 3 and 4). Incidentally, co-expression of DP-35 with HA-E2F-5 resulted in 
stabilization of the two slowest migrating bands corresponding to hyper- 
phosophorylated species of E2F-5 (Morris et al., 2000) as detected by western blot 
(Figure 4.5-B, compare lanes 1 and 2, bands indicated with a asterisks). However, co­
expression with DP-35Ab gave a different display of bands with the two top bands less 
abundant and the appearance of a stronger lower hypo-phosphorylated band. The 
significance of this is unclear but implies that DP has an influence on the 
phosphorylation of B2F-5.
Both DP and E2F proteins contain sequence-specific DNA binding domains, 
located in similai' positions of each protein (Girling et ah, 1993). Heterodimerisation 
results in co-operative recognition of, and activation of transcription through, the E2F 
binding site. Since the basic region was located close to the DNA binding domain of
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Removal of the basic region from DP-36 does not alter the DNA binding 
activity of E2F
Whole cell extracts o f  U 20S  cells transfected with the indicated expression  
plasmids were used in gel shift DNA binding assays with a 32? labelled oligonucleotide 
containing an E2F binding site (see section 2-1.11.). (A) Shows binding o f E2F-1 complexes 
to DNA. DNA binding reactions in lanes 4, 6, 8 and 10 were subjected to supershift by rabbit 
polyclonal anti-E2F-l antibody KH95. * indicates the postion o f the shifted complex. NS 
indicates non-specific binding to the probe. Note that lane 5 was incubated with more cold 
probe competitor.
(B) Shows binding o f E2F-5 complexes to DNA.
DP it was imperative to assess the ability of DP-35Ab to cooperate with E2F in DNA 
binding. This was determined using gel retardation assays with transfected COS-7 cell 
extracts. An antibody to E2F-1 was used to super-shift DNA binding complexes 
containing E2F-1. Figure 4.6-A shows formation of DNA bound heterodimers of E2F- 
1 with DP-3P (lanes 5 and 6), DP-35 (lanes 7 and 8) and DP-35Ab (lanes 9 and 10). 
All three DPs increased the DNA binding ability of E2F-1 synergistically (compare 
lanes 3 and 4 with 5,6,7,8,9, and 10). The observed levels of DNA bound complex 
coiTelated with the relative expression levels of each protein. Formation of a DNA 
binding complex of DP-35Ab with E2F-5 was also assessed. Figure 4.6-B shows that 
DP-35Ab co-operated with E2F-5 to form a DNA bound complex as well as wild type 
DP-35 did. Observed levels of complex con-elated with relative expression levels of 
each protein. Therefore, the basic region of DP-35 is not involved in the association 
with E2F and does not influence the heterodimers ability to bind to specific DNA sites 
under the conditions used.
4-3. Conclusion
Although the E region is necessary for nuclear accumulation of DP, it is not 
sufficient to target a protein to the nucleus. A basic region, C- terminal to the E region, 
which is conserved in all DPs, was also required. Evidence supporting the theory that 
these two elements form a bipartite NLS comes from the fact that removal of the basic 
region from DP-35 altered the protein from a nuclear to a cytoplasmic phenotype. DP- 
35 Ab exhibited the properties expected of a cytoplasmic non-NLS containing protein
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since it was unable to transport NLS-containing E2Fs to the nucleus. However, unlike 
other cytoplasmic DPs, hetrodimerisation with an NLS-containing E2F was not 
sufficient to induce nuclear accumulation of DP-3ôAb in SV40 T antigen transformed 
cells. DP-30Ab was able to co-localise to the nucleus with a non-NLS containing E2F 
that was bound to pocket protein, implying that downstream E2F functions are 
regulated differently after pocket protein-mediated nuclear transport compared with free 
E2F nuclear transport.
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Chapter 5. DP mediates the association of E2F with 
14" 3"3
5-1. Introduction
With a view towards understanding the role of the DP subunit in the E2F 
heterodimers it was reasoned that the basic region may be involved in regulating the 
interaction of the DP subunit with another protein. To test this hypothesis, a yeast two- 
hybrid system was used to conduct an in vivo search for a gene encoding a protein that 
interacts with DP-35 but not with DP-35Ab and which may contribute to the properties 
of this region described in the previous chapters. The results have uncovered a new 
interacting protein for E2F that integrates the E2F pathway with other growth control 
pathways.
5-2. Results
5-2.1. Yeast two-hybrid screening
A yeast two-hybrid strategy, described in Material and Methods 2-1.10, was 
employed to identify DP interacting proteins where the efficiency of interaction was 
dependent on whether the basic region was present. Figure 5.1-A illustrates the 
screening system used. A yeast colony phenotype becomes LacZ+, i.e. blue in colour
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(A) Strategy for isolating interactants with DP3Ô but not DP-3ôAb. Interaction 
b etw een  bait and library protein  turns yeast co lon y  b lue in the p resence  
o f  (3-galactosidase substrate.
(B ) D iagram m atic rep resen ta tion  o f  bait and prey used  in assay .
upon exposure to an X-Gal substrate, when the LexA DNA binding domain (DBD) and 
the VP16 activation domain (AD) are brought into close proximity in the promoter 
region of the lacZ gene. This only occurs if there is an interaction between the bait and 
a library protein. The “baits” were either a fragment of DP-35 or DP-35Ab (amino acids 
1-110 or equivalent region in DP-35Ab) fused to the LexA DNA binding domain 
(Figure 5.1-B). Yeast cells were analysed for LexA-dependent transcription activity 
following co-transformation of the bait plasmid with a 14.5 dpc mouse embryo cDNA 
libraiy fused to the VP16 activation domain (Figure 5.1-B).
The sequence of one resulting positive clone revealed the epsilon isoform of 14-
3-3. Figure 5.2-B shows the region of 14-3-3e , isolated from yeast, after DNA 
sequencing and matching to known proteins in the GenBank nucleotide database. 
Results of the (3-gal assay shown in figure 5.2-Ai coiTespond to the transformations 
listed in Figure 5.2-Aii. Only filter 3 (Figure 5.2-A) had blue colonies signifying that 
DP-35 interacted with 14-3-3e whereas DP-35Ab failed to interact with 14-3-3e. The 
interaction between LexA-DBD-DP35 and VP-16-AD-14-3-3 was specific as binding 
was not apparent between 14-3-3 and the LexA-DBD or between DP-35, or DP35Ab 
and the VP-16-AD.
5-2.2. 14-3-3 association with E2F is regulated through DP
Since 14-3-3 was isolated by screening in a yeast two-hybrid assay for proteins 
that required the basic region for an interaction with DP-35, a biochemical approach 
was next taken to assess if DP-35 could physically interact with 14-3-3e. First of all the
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(A )(i) Filters o f  yeast cells transformed as in table (ii) showing VP 16 dependent 
transcriptional activity o f  an integrated P-galactosidase reporter as a blue colony, 
(ii) Summary o f  results from the interaction studies performed in yeast using the indicated 
bait and prey.
(B ) R eg ion  o f  1 4 -3 -3 e  id e n tif ied  in y ea st tw o hybrid assay  resu lts .
interaction was confirmed using GST pull-down experiments with transiently 
transfected COS-7 cell extracts and bacterially expressed GST-14-3-3 6 or GST alone 
(Figure 5.3-Ai), and binding efficiency measured thereafter. In these experiments, HA- 
E2F-5 was retained by GST-14-3-36 when in the presence of DP-35. However, HA- 
E2F-5 was not retained when co-expressed with DP-35Ab. Although the amount of 
E2F-5 pulled down by GST-14-3-3e was low when in the presence of DP-35, DP-35Ab 
heterodimers always scored negative in this assay. GST alone was unable to bind to 
E2F-5. Immunoblotting for DP-3 showed that GST-14-3-3e pulled down DP-35 
(Figure 5.3-B lane 3). Although a low amount of DP-35Ab protein was detected in the 
GST-14-3-3 precipitate (Figure 5.3-B lane 4), it should be noted that the input lanes 
show that higher levels of DP-35Ab protein were present in the assay (Figure 15-B, lane 
2 compared to lane 1).
Next, the association was tested in mammalian cells using the two-hybrid 
approach. Gal4-dependent transcription activation was followed after transfecting 
U20S cells with VP16-AD-tagged 14-3-36 and Gal4-DBD-tagged DP-35 or DP-1. 
Significant stimulation of activity was apparent when VP16-14-3-38 was co-expressed 
with G4-DP-35 and not with G4-DP-1 (Figure 5.4, compare lanes 2 and 3 with 4 and 5). 
These data suggest that the interaction between the E2F transcription factor and 14-3-3 
is determined by the choice of DP paitner.
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Figure 5.3
14-3-3e binds to the E2F-5/DP-3Ô heterodimer but not the E2F 5/DP 30Ab 
heterodimer in vitro.
(A )(i) C oom assie stained bacterially expressed GST protein ( la n e l)  and 
GST-14-3-3e protein (lane 2). Transfected whole cell extracts were incubated with Ipg 
GST-14-3-3e immobilised on glutathione agarose beads and preciptitates subjected to 
SDS-PAGE and immunoblotted with anti-HA antibody (A )(ii) or anti-DP-3 peptide 
antibody (B).
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Figure 5.4
14-3-3 associates with DP-36 but not efficiently with DP-1
(A) Mammalian two hybrid interaction assay between DP fused to a GAL4 DNA  
binding domain and 14-3-3 fused to the /ran^-activation domain o f  VP16. Results are 
presented as activity o f  a G 5Elb5 luciferase reporter construct containing GAL4 DNA  
binding sites. Each bait was co-expressed with VP 16AD alone (lanes 2 and 4) or with 
VP 16-14-3-3 (lanes 3 and 5). A ll plates were cotransfected with pCMVPgal as internal 
co n tro l. V a lu es are g iv en  as the ratio  o f  lu c ife r a se  to |3gal a c t iv it ie s .
5-2.3. The basic region is involved in association of 14-3-3 with E2F
To show that the basic region of DP is influential in the association of E2F with 
14-3-3 in mammalian cells, immunoprécipitation experiments were earned out on 
U20S cells transfected with HA-E2F-5 and either DP-35 or DP-35Ab. As expected, 
western blotting analysis of the inputs showed greater protein levels of DP-35Ab/ E2F-5 
heterodimer than the DP-35/E2F-5 heterodimer but equal protein levels of endogenous 
14-3-3 protein (figure 5.5-A, compare lanes 1 and 2, top blot shows DP-3 and 14-3-3 
protein levels, bottom blot shows E2F-5 levels). The 14-3-3 antibody is directed 
towards a common motif found in all isoforms of 14-3-3. Immunoprécipitation of HA- 
E2F-5 with the anti-HA monoclonal antibody resulted in co-precipitation of both wild 
type and mutant DP-3; as detected by a rabbit polyclonal antibody to DP-3, equivalent 
to their input levels, implying equal binding (Figure 5.5-A). Nevertheless, co- 
immunoprecipitation of endogenous 14-3-3, as detected by a rabbit polyclonal antibody 
to 14-3-3, was greater from the extract expressing wild type DP-35 compared to the 
extract expressing mutant DP-35 (Figure 5.5-A, compare lanes 3 and 4). Again, 
although a low amount of 14-3-3 protein was precipitated from the extract expressing 
the mutant DP-3d (Figure 5.5-A lane 3), it should be noted that the input lanes show 
that far higher levels of DP-35Ab protein were present in the assay (Figure 5.5-A, lane 3 
compared to lane 4). Western blot shows a preference for the upper isoform of 14-3-3 
in the immunoprecipitate.
Reciprocal immunoprécipitation, utilizing the rabbit polyclonal anti-14-3-3 
antibody resulted in co-precipitation of HA-E2F-5 when co-expressed with wild type
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Figure 5.5
The basic region of DP-3Ô is necessary for association of heterodimer with 14-3-3
(A) Immunoprécipitation o f  endogenous 14-3-3 with exogenous DP-3 from 
extracts o f cells transfected with HA-E2F-5 and DP-3. Extracts were immunoprecipitated 
using an anti-HA monoclonal antibody and proteins detected with a polyclonal anti-DP-3 
antibody and a polyclonal anti-14-3-3 antibody raised against a peptide common to all 
14-3-3 isoforms. Inputs (lanes 1 and 2) show amounts o f  exogenous HA-E2F-5 and DP-3 
proteins expressed. Positions o f DP-3 and 14-3-3 proteins are indicated. Note that only the 
upper band o f 14-3-3 is precipitated (lane 4).
(B) Immunoprécipitation o f  exogenous HA-E2F-5 from cells transfected with 
HA-E2F-5, DP-3 and myc-tagged 14-3-3e. Extracts were immunoprecipitated using an 
anti-14-3-3 polyclonal antibody and proteins detected with a m onoclonal anti-HA  
antibody. Inputs (lanes 1 and 2) indicate amounts o f HA- E2F-5 and endogenous and 
exogenous 14-3-3 proteins expressed.
(C) Im m unoprécipitation o f  exogenou s m yc-tagged  14-3-3e from ce lls  
transfected  w ith  H A -E 2F -5 , DP-3 and m yc-tagged  14 -3 -3 e . E xtracts w ere  
immunoprecipitated using an anti-DP-3 polyclonal antibody and proteins detected with 
a monoclonal anti-myc antibody (9E10).
DP-35 but not when co-expressed with the mutant DP-30Ab (Figure 5.5-B, compares 
lanes 3 and 4). The extracts used in this particular experiment contained a similar level 
of E2F-5 protein, as detected by an anti-HA antibody, however, it should be noted that 
the pattern of bands differs between the two samples. As observed previously in figure 
4.5-B, the top two hyper-phosphorylated species of E2F-5 observed in the wild type 
heterodimer are less evident in the extract expressing DP-35Ab/HA-E2F-5 (Figure 5.5- 
B, top blot, compai'e lanes 1 and 2). Equal levels of endogenous and exogenous 14-3-3 
were expressed between the two samples (Figure 5.5-B, bottom blot, compare lanes 1 
and 2). Similar results were obtained in an anti-myc immunoblot of proteins 
immunoprecipitated with an anti-DP-3 antibody from cells transfected with HA-E2F-5, 
myc-tagged 14-3-3e and either DP-35 or DP-35Ab (Figure 5.5-C).
5-2.4. 14-3-3 co-Iocalises with DP-3 in the nucleus
14-3-3 has been shown to function as an attachable nuclear export signal that 
enhances the nuclear export of Cdc25 (Lopez-Girona et a l, 1999) and a forkhead 
transcription factor in response to phosphorylation by AKT (Brunet et a l, 1999), 
therefore, the cellular location of DP-35 was assessed in COS-7 cells after transient 
transfection with myc-tagged 14-3-38. Results showed that 14-3-38 is a cytoplasmic 
protein (Figure 5.6-A). After the addition of DP-35, an increase in nuclear staining of 
14-3-3 was observed, (Figure 5.6-Bi) coirelating with the co-expression of nuclear DP- 
35 within the same cell (Figure 5.6-Bii). This illustrated that 14-3-3 does not retain DP- 
3 in the cytoplasm, as may be assumed from previously documented examples, but that 
expression of DP-35 can drive 14-3-3 proteins into the nucleus.
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14-3-3 is a cytoplasmic protein which accumulates in the nucleus with E2F-5/DP-3Ô
(A) The intracellular distribution o f exogenously expressed myc-tagged 14-3-3e 
d etected  by im m u n o flu o r esce n c e  u s in g  a m o n o c lo n a l a n ti-m y c  an tibod y .
(B ) M yc-tagged  14-3-3  co -exp ressed  w ith DP-3Ô detected  by im m uno­
fluorescence using a polyclonal anti-DP-3 peptide antibody (ii) and amonoclonal anti- 
myc antibody (i) in cells expressing both proteins.
5-3. Conclusion
14-3-3 molecules are highly evolutionarily conserved and expressed in a wide 
range of tissues and cell-types (Aitken, 1996). They are thought to play key roles in 
signal transduction pathways as scaffolding or adapter proteins that bring together 
signalling molecules. E2F associated with 14-3-3 via the DP-component in various 
different assays. This interaction required an intact basic region. Although little is 
known about the biological function of 14-3-3 proteins, the crystal structure of two 
isoforms has been solved (Liu et a l, 1995; Xiao et al., 1995). These structures suggest 
that 14-3-3 proteins exist as dimers, with each monomer containing nine helices that 
surround a groove (Figure 1.8). One interpretation of the crystal structure suggests that 
the groove could accommodate an amphipathic helix (Liu et ah, 1995). Elucidation of 
the crystal structure of DP-3 will answer whether the basic region is involved in the 
formation of an amphipathic helix. Many proteins bind to 14-3-3 subsequent to 
phosphorylation either within the binding region or flanking it (Muslin et ah, 1996; 
Yaffe et al, 1997). The basic region of DP-3Ô is within a domain rich in serine residues 
so its possible that phosphorylation here may regulate binding to 14-3-3.
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Chapter 6. 14-3-3 regulates the cell cycle through
E2F
6-1. Introduction
The previous chapter identified 14-3-3 as a novel interacting protein for E2F. 
14-3-3 molecules are known to provide a platform to promote communication between 
proteins involved in a myriad of signalling pathways. However, the exact functions of 
14-3-3 molecules are poorly understood and no inherent biological function has been 
attributed to them.
The aim of this chapter was to identify a role for 14-3-3 in the regulation of E2F 
activity. This was achieved by characterising the phenotype of a mutant DP that does 
not bind to 14-3-3. The results propose a role for 14-3-3 in promoting cell-cycle 
progression through the E2F pathway.
6-2. Results
6-2.1. 14-3-3 influences E2F transcriptional activity
Firstly, the effects of 14-3-38 on E2F site-dependent transcription by DP-3/E2F- 
1 and DP-3/E2F-5 were assessed. 14-3-3e was co-expressed with E2F-1 or E2F-5 and
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either DP-3Ô or DP-3ôAb and the influence on transcriptional activity of the cyclin E 
promoter, a cellular promoter that is known to be E2F responsive (Botz et al., 1996; 
Geng et al., 1996) was deteiTnined. DP-3(3, DP-35 and DP-35Ab clearly co-operated 
with E2F-5 in activation of the cyclin E promoter (Figure 6.1-A, lanes 2, 4 and 6). 
Repeatedly, DP-3ôAb/ E2F-5 gave a 50% reduction in transcriptional activation 
compared to both the NLS-containing DP-35 and the non-NLS-containing DP-3(5. Co­
expression of 14-3-38 with E2F-5 and either DP-3p or DP-35 caused a considerable 
increase in the level of E2F-site dependent transcription (Figure 6.1-A, lanes 3 and 5). 
However, 14-3-38 was unable to significantly increase the activity of the DP-35Ab/E2F- 
5 heterodimer, supporting the idea that the basic region is required for 14-3-3 to interact 
with, and exert a functional consequence upon the E2F transcription factor.
Contrasting results were obtained for the E2F-1 heterodimer. Titrating 14-3-38 
on top of a DP-35/E2F-1 heterodimer remarkably reduced transcriptional activity of the 
E2F to almost background levels. However, 14-3-38 actually increased the activity of a 
DP-35Ab/E2F-l heterodimer.
In summary, 14-3-38 appears to stimulate E2F site-dependent transcriptional 
activity of an E2F-5 heterodimer, conceivably by providing a growth signal that also 
results in reducing the activity of an E2F-1 heterodimer. The basic region influences 
these effects.
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Figure 6.1
The DP component influences 14-3-3 effects on E2F transcriptional activity
The indicated expression vectors were transfected into U 2 0 S  cells and the 
activity o f  a luciferase reporter, which carries E2F binding sites from the cyclin E 
promoter, assessed. (A) shows effects on E2F-5 /ran^-activation and (B) shows effects 
on E2F-1 trans-diCixwdLÛon.
6-2.2. Transcriptional activity of E2F relates inversely to protein levels
As shown in previous figures (Figure 5.3-B , lanes 1 and 2, and Figure5.5-A, 
lanes 1 and 2), DP-35Ab is more abundant than DP-3Ô in transfected cell extracts, as is 
E2F-5 when co-expressed with DP-3ôAb. However, transcriptional activation of the 
cyclin E-luciferase reporter construct in cells transfected with the DP-3ôAb/E2F-5 
heterodimer was much lower than in cells transfected with the DP-3Ô/E2F-5 
heterodimer (Figure 6.2-A). Increasing levels of wt DP-35 eventually caused a decrease 
in activation of the reporter, suggesting that this ‘squelching’ effect may be observed 
with a lower amount of mutant DP-3. This implied that lower levels of mutant DP-3 
might cause an equivalent level of activation seen at greater levels of the wt DP-35. 
However, this was not the case: cells transfected with lower amounts of the mutant 
failed to activate the reporter (results not shown). Figure 6.2-B shows levels of E2F-5 
protein after transient transfection in U20S cells and the corresponding effect on an 
E2F-si te-dependent reporter. E2F-5 alone had little effect on the reporter and low levels 
of the protein were detected in a western blot (Figure 6.2-B lane 1). Upon addition of 
DP-35, E2F appears stabilised as heterodimerisation and DNA binding occur and an 
obvious synergistic increase in transcriptional activity was observed (Figure 6.2-B lane 
2). In the presence of DP-35Ab, E2F-5 levels were increasingly stabilised but the 
transcriptional activity had decreased (Figure 6.2-B lane 3). In accordance with figure 
6.2-A, increasing the levels of E2F components resulted in a reduction in transcriptional 
activation. When 14-3-3 was co-transfected, transcriptional activation increased, 
however, E2F-5 protein levels decreased (Figure 6.2-C, compare lanes 2 and 3), This 
suggests that the basic region-dependent association of 14-3-3 with the DP component
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Figure 6.2
Removing the basic region from DP reduces transactivation of an E2F site 
d ep en d en t rep orter  a lth ou gh  the h eterod im er is more abundant
(A)Titration o f  DP-36 (red line) or DP-36Ab (green line) co-transfected with 
E2F-5 transactivating a luciferase reporter which carries an E2F binding site from the 
cyclin E promoter.
(B) and (C) Reporter assays carried out in U 20S  cells transfected as indicated. 
Extracts were also immunohlotted with anti-HA and anti-m yc antibodies to show  
expression o f  exogenous HA-E2F-5 and 14-3-3myc.
of E2F, causes an increase in E2F dependent transcriptional activity by inducing 
degradation of the heterodimer.
6-2.3. The basic region influences the half-life of DP
When transfected cell extracts conected for transfection efficiency, were 
subjected to immunoblotting, DP-S^Ab and DP-3ôAb protein levels were more 
abundant than their respective wild-type counterparts (Figure 6.3-A, compare lane 1 
with 2 and 3 with 4). It was reasoned that this might be due to an increase in stability of 
the mutant protein. The degradation of the mutant DP was compared with the wild type 
DP by western blot analysis of transfected cell extracts after treatment with the 
translation inhibitor cyclohexamide. While the wild type DP-3Ô and DP-3P 
disappeared with a half-life of around 30-60 min (Figures 6.3-B and -D respectively), 
the mutant DPs remained stable throughout the time-course (Figure 6.3-B and -D). The 
determination of half-life under these conditions is only a rough estimate since treating 
cells with cyclohexamide not only blocks the de novo synthesis of DP but also the 
synthesis of proteins required for proteolysis. Nonetheless, the differences in stability, 
attributed to the basic region were striking.
6-2.4. The basic region of DP influences half-life of E2F
Since the basic region regulates degradation of DP, the role of the basic region 
within the context of a heterodimer was assessed. When equally transfected cell 
extracts were subjected to immunoblotting with an anti-HA antibody, E2F-5 levels were
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Figure 6.3
The basic region of DP influences protein stability by regulating half-life
(A) Extracts o f  cells, transfected as indicated, were loaded equally for transfection 
efficiency and subjected to immunoblotting by an anti-DP-3 peptide antibody to detect 
exogenous protein.
(B) and (D) Immunoblots o f  transfected cell extracts. One pi 00 was transfected 
with indicated expression plasmids then split into 5 (B) or 4 (D) p60s to maintain equal 
transfection efficiency between sam ples. Cells were treated with cyclohexam ide for 
tim es indicated before harvesting . N ote  that protein lev e ls  betw een d ifferent 
transfections in (B) and (D) are not comparable.
(C) Relative abundance o f  DP-3 protein in (B).
(E) Relative abundance o f DP-3 protein in (D).
higher when expressed with DP-3(3Ab and DP-3ôAb than when expressed with their 
wild-type counterparts (Figure 6.4-A, compare lane 2 with 3 and 4 with 5), It appears 
that the stable basic deletion mutants possess the ability to increase the stability of an 
associated E2F partner. The degradation of E2F-5, in the presence of the wild type or 
mutant DP, was assayed by immunoblotting transfected cell extracts after treatment 
with cyclohexamide. Figure 6.4-C shows quantification of blots 1-4 in figure 6.4-B. 
Transfection 1 (DP-36 and E2F-5) showed E2F-5 had a half-life of around 100 min 
while transfection 2 (DP-3ôAb and E2F-5) had a very stable E2F-5, even after 2 hours. 
In the presence of exogenous 14-3-3, the half-life of E2F-5 became shortened to around 
60 min when co-expressed with the wild type DP-36 (transfection 3), but remained 
stable when co-expressed with the mutant DP-36 (transfection 4), These data indicate 
that DP regulates the degradation of E2F-5 and that 14-3-3 enhances this degradation. 
Removing the basic region resulted in a more stabilised heterodimer, which no longer 
responded to 14-3-3.
6-2.5. DP is degraded by the ubiquitin-proteasome mediated pathway
To determine whether DP-36 is degraded by the ubiquitin-proteasome pathway, 
the abundance of exogenous DP-36 protein in cells that had been exposed to a 
proteasome-specific inhibitor, LLnL (Rock et al., 1994) was compared with the level of 
exogenous DP-36 protein in cells that had not been exposed to the inhibitor. COS-7 
cells were treated for 2 hours with 50mM LLnL or with the solvent DMSO. As shown 
in figure 6.5-A, LLnL treatment led to a marked increase in DP-36 abundance (compare 
lanes 2 and 3) but had little effect on DP-36Ab abundance (compare lanes 5 and 6).
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Figure 6.4
The basic region of DP influences E2F protein stability by regulating half-life
(A) Extracts o f  cells, transfected as indicated, were loaded equally for 
transfection efficiency and subjected to immunoblotting by an anti-HA antibody to detect 
exogenous E2F-5 protein,
(B) Immunoblots o f transfected cell extracts. One pi GO was transfected 
with the indicated expression  plasm ids then split into 3 p60s to maintain equal 
transfection efficiency between samples. Cells were treated with cyclohexam ide for 
times indicated before harvesting. Positions o f  HA-E2F-5 and 14-3-3-m yc are shown. 
Note that protein levels between different transfections in (B ) are not eomparable.
(C) Graph showing rate o f  degradation o f  E2F transfections in (B).
Figure 6.5-B investigates the contribution DP-3Ô makes to 14-3-3-mediated 
degradation of the heterodimer. In the presence of an E2F partner, DP-3Ô protein was 
stabilised (compare figure 6.5-A, lane 1 with figure 6.5-B, lane 4), while DP-3ôAb 
protein levels remained similar to those observed when DP-35Ab was expressed alone 
(compare figure 6.5-A, lane 4 with figure 6.5-B, lane 10). When 14-3-3 was also 
expressed (Figure 6.5-B), the relative abundance of DP-3Ô decreased, whereas DP-3ôAb 
protein levels remained high. This decrease in DP-3Ô protein abundance, in the 
presence of 14-3-3 can be attributed to degradation via the ubiquitin-proteasome- 
mediated pathway since the addition of LLnL restored protein levels (Figure 6.5-B 
compare lanes 2 and 3). 14-3-3 had little effect on the DP-3ôAb heterodimer abundance 
and so LLnL effects were insignificant.
6-2.6. The basic region is required for cell cycle progression by E2F.
Since it is known that over-expression of E2F promotes cell cycle progression 
(Beijersbergen et a l, 1994; Shan and Lee, 1994) it was important to ascertain the 
effects of the stabilised E2F heterodimer on cell cycle progression. To investigate this, 
wild type or mutant DP-3Ô was transfected alone, or with E2F-5, into the human 
osteosarcoma cell line U20S, together with the cell surface marker CD20. Transfected 
cells were identified with an anti-CD20 antibody, and their DNA content was assayed 
by flow cytometry analysis to determine cell cycle distribution. The introduction of 
DP-3Ô into cells reduced the fraction of G1 cells with concomitant increases in S-phase 
and G2/M-phase populations (Figure 6.6), suggesting that DP-35 stimulates cell cycle 
progression. These effects were similar to those reported in previous studies (Wu et al.,
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14-3-3 destabilises E2F via the ubiquitin-proteasome mediated degradation pathway
One p i 00 was transfected with expression plasm ids indicated then split into 
three p60s to maintain equal transfection efficien cy  between sam ples. C ells were 
subjected to either LLnL, DMSO (solvent for LLnL) or untreated for 2 hours before 
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Figure 6.6
The basic region of DP is necessary for efficient progression into S-phase
U 20S  cells, transfected with the indicated plasmids, were analysed by flow 
cytometery to determine the cell cycle profiles o f  CD20 - positive cells. The data are 
presented as the percentage change o f cells in each phase o f the cell cycle relative to 
C D 20 ex p ress in g  c e lls  tran sfected  w ith  em pty ex p ress io n  p lasm id .
1996). This effect was also achieved by co-expressing E2F-5 with DP-35, although 
alone, E2F-5 had little effect on the cell cycle (data not shown). Expression of DP- 
35 Ab caused a marked difference in cell cycle profile. Although the fraction of cells in 
S-phase increased slightly, neither a reduction in the G1 fraction or an increase in the 
G2/M population was observed. This implied that cells were initially stimulated to 
enter S-phase, but a subsequent increase in G2/M phase population did not follow, 
therefore as DP-35Ab protein levels rose, cells became stuck in S phase. Cells with 
high levels of DP aie impaired in their ability to exit S-phase. Therefore, degradation of 
the E2F transcription factor, mediated by 14-3-3 through the basic region of DP3, is 
necessary before cells with high levels of E2F can progress through the cell cycle.
6-3. Conclusion
The basic region, having been defined in the previous chapter, as influencing the 
association between 14-3-3 and the E2F transcription factor, was shown to be required 
for 14-3-3 mediated effects on E2F transcriptional activity, protein turnover, and cell- 
cycle progression. Removing the basic region from DP resulted in a more stable E2F 
heterodimer that had lower transcriptional activity, and was less competent in pushing
cells through the cell cycle. This may suggest a role for 14-3-3, in a growth 
promoting pathway, mediating the degradation of E2F via the ubiquitin-proteasome- 
mediated pathway in S-phase allowing cells to progress into G2/M-phase.
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Chapter 7. The search for the phosphoserine 14-3-3 
binding region within DP
7-1. Introduction
This thesis has reported the importance of the basic region in the regulation of 
the association between 14-3-3 and DP. This region has also been shown to be required 
for 14-3-3-dependent functional regulation of the E2F transcription factor. It was 
therefore important to determine the nature of the 14-3-3 binding interaction. Recent 
findings have suggested that 14-3-3 interactions involve binding to discrete 
phosphoserine-containing motifs (Muslin et a l, 1996; Yaffe et a l,  1997). This implies 
that 14-3-3 could function in a manner analogous to SH2 domains; 14-3-3 binding to a 
specific phosphoserine motif could result in the assembly of important signalling 
complexes.
The aim of this chapter was to identify a phosphoserine-containing motif within 
DP that could mediate an interaction with 14-3-3. To this end, single-site mutagenesis 
was used to mutate putative phospho-serines to alanines (see materials and methods 2- 
1.14). Assuming that the basic region was involved in direct association with 14-3-3, 
serines 61 and 75 appeared plausible phosphorylation targets, which may mediate 
association with 14-3-3. Ser61 is located within the basic region, and Ser75 lies 
immediately C terminal to the basic region (Figure 7.1).
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Figure 7.1
Potential 14-3-3 phosphoserine binding motifs in DP-36
Diagrammatic representation o f  single-site serine to alanine mutations in DP-36; 
DP-36S61A and DP-36S75A.
Diagram also illustrates the conservation o f  the mutated serine residues between all the 
DP family and their positions relative to the E region and the basic region.
7-2. Results
7-2.1. Serines 61 and 75, in DP-36, are not required for heterodimerisation 
with E2F
Before assessing their 14-3-3-binding status, the DP-36 mutants, DP-36S6iA and 
DP-3ÔS75A, were assayed for their E2F heterodimerisation capabilities. Gel retardation 
assays, with transfected COS-7 cells extracts, showed that the mutant DP-3ÔS75A was 
able to bind DNA cooperatively with either E2F-1 or E2F-5 as efficiently as its wild- 
type counterpart did (Figure 7.2-A compare lane 5 with 3 for E2F-5 complex, and lane 
8 with 6 for E2F-1 complex). This demonstrated that Ser75 within DP-36 was 
dispensable for both heterodimerisation with an E2F partner and for sequence specific 
DNA binding.
Figure 7.2-B shows that Ser61 within DP-36 is also dispensable for 
heterodimerisation with an E2F partner. DP-36SôiA, DP-36, DP-36Ab, E2F-1 and E2F- 
5 DNAs were in vitro transcribed and translated and immunoprécipitation experiments 
performed (Figure 7.2-B, lanes 1-6 show the relative expression of E2F and/or DP in 
the lysates used in the immunoprécipitations in lanes 7-12).
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Figure 7.2
Mutation of serine 61 or serine 75 in DP-36 does not alter heterodimerisation of E2F
(A) Whole cell extracts o f  U 20S  cells transfected with the indicated expression 
plasmids were used in gel shift DNA binding assays with a 32P-labelled oligonucleotide 
containing an E2F binding site (see section 2-1.11.).
(B) Immunoprécipitation o f  HA-tagged E2F-5 and DP-3 from 35S-labelled in 
vitro  translated rabbit reticulocyte lysates using a polyclonal anti-DP-3 peptide antibody, 
and proteins detected by autoradiography. The postitions o f  the labelled proteins are 
shown.
Results showed that E2F-1 and E2F-5 were both recovered efficiently in anti-DP-3 
immunoprecipitates from lysates containing DP-35, DP-3ôAb or DP-35S6iA suggesting 
that stable complexes of each DP-3 formed with E2F-1 (Figure 7.2-B, lanes 10, 11 and 
12), and E2F-5 (Figure 7.2-B, lanes 6, 7 and 8). Thus, DP-35S6iA can form stable 
complexes with E2F-1 and -5 in vitro.
7-2.2. Ser61 and Ser75 of DP-35 are not involved in cellular localisation of the 
E2F transcription factor
Mutating either Ser61 or Ser75 in DP-35 to an alanine residue did not affect the 
cellular localisation of the DP protein. Like the wild-type protein, both mutants gave a 
nuclear phenotype when transfected into COS-7 cells with expression detected by 
indirect immunofluorescence (Figure 7.3-A). When co-expressed with HA-E2F-1, all 
the DP-3s co-localised with E2F-1 in the nucleus (Figure 7.3-B). Both mutants were 
also able to transport a cytoplasmic E2F, E2F-5, into the nucleus (Figure 7.3-C). These 
results demonstrate that mutation of either Ser61 or Ser75 in DP-35 does not affect the 
cellular transport, of these proteins, or of a heterodimer containing either one of these 
mutants.
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Figure 7.3
Serine61 and serine75 of DP-3Ô are net involved in nucleocytoplasmic targeting of 
the E2F transcription factor
(A) The intracellular distribution o f  exogenously expressed DP-36, DP-36S61A 
or DP-36S75A was detected by immunofluorescence using a rabbit polyclonal anti-DP-3 
antibody.
(B) The intracellular distribution o f  exogenously co-expressed DP-36 (i and ii), 
DP-36S61A (iii and iv) or DP-36S75A (v and v i) with HA-E2F-1 was detected by 
immunofluorescence using a rabbit polyclonal anti-DP-3 antibody (i, iii and v) and a 
mouse monoclonal anti-HA antibody (ii, iv and vi).
(C) The intracellular distribution o f  exogenously co-expressed DP-36 (i and ii), 
DP-36S61A (iii and iv) or DP-36S75A (v and v i) with HA-E2F-5 was detected by 
im munofluorescence using a rabbit polyclonal anti-DP-3 antibody (i, iii and v) and a 
mouse monoclonal anti-HA antibody (ii, iv and vi).
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Figure 7.4
M utation of serine 61 or serine 75 of DP-36 to alanine does not 
block 14-3-3 effects on E2F transcriptional activity
The indicated expression vectors were transfected into U 2 0 S  cells and the 
activity o f  a luciferase reporter, which carries E2F binding sites from the cyclin E 
promoter, assessed.
7-2.3. 14-3-3 effects on the transcriptional activity of E2F are not mediated
through Serine61 or SerineVS of DP-35
As shown previously (Figure 6.1), 14-3-3 stimulated E2F-dependent 
transcriptional activity of an E2F-5 heterodimer (Figure 7.4-A compare lanes 2 and 3; 
Figure 7.4-B eompare lanes 2 and 3). Transcriptional activity of the E2F-5 heterodimer 
with either the Ser75 or the Ser61 mutant DP-3 was similar to that of the wild-type 
protein (Figure 7.3-A compare lanes 2 and 4; Figure 7.4-B compare lanes 2 and 6). 
Increased activation of the heterodimer by 14-3-3 was also unaffected by the mutations 
in DP-35 (Figure 7.4-A compare lanes 3 and 5; Figure 7.4-B compare lanes 3 and 7). 
Figure 7.4-B, lanes 4 and 5, also show the transcriptional activity of the basic deletion 
mutant DP-35Ab and the effect of 14-3-3 on activation of this heterodimer for 
comparison with the other mutants. These results suggest that neither Ser61 nor Ser75 
are required for 14-3-3 effects on E2F transcription factor activity.
7-3. Conclusion
As the basic region has been identified as a critical component in the regulation 
of the interaction between 14-3-3 and DP, it was reasoned that a phosphoserine- 
containing 14-3-3 binding motif may be located in that region. However a mutant DP- 
35 incapable of phosphorylation at either Ser61 within the basic region, or Ser75 just 
out with the basic region, did not abolish 14-3-3-dependent effects on E2F
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transcriptional activity. This suggests that the association of 14-3-3 with DP is not 
dependent upon phosphorylation at either of these two sites.
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Chapter 8. Discussion
8-1. Nuclear accumulation of the E2F heterodimer
The E2F heterodimer is known to be regulated on a number of different levels, 
such as binding and transcriptional repression by pocket proteins (Flemington et al,
1993), phosphorylation by cdk complexes (Ki'ek et al., 1994, 1995) and transcriptional 
activation by the MDM2 oncoprotein (Martin et a l, 1995). Here, I have shown that an 
additional mechanism of control in regulating the activity of E2F is mediated at the 
level of intracellular location. Specifically, these data show that nuclear accumulation 
of the E2F/DP heterodimer is regulated by an alternatively spliced nuclear localisation 
signal in the DP component and also through subunit composition of the transcription 
factor (Figure 8.1). Since transcription factors exert their effects on gene expression in 
the nucleus, control of intracellular location is an important regulatory mechanism.
By investigating their intracellular distribution, it was possible to divide the E2F 
family into two distinct classes according to their ability to accumulate in nuclei. The 
first group, exemplified by E2F-1, underwent efficient nuclear accumulation whereas 
the second, which includes E2F-4 and -5, failed to do so and remained, for the most 
part, in the cytoplasm. In support of these findings, a NLS has been identified in E2F- 
I, -2 and -3  in the N-terminal region, a domain absent from E2F-4 and -5 (Ki'ek et a l,
1994). The non-NLS containing E2F family members therefore rely on other proteins 
to provide NLS activity. These observations are in accordance with previous studies 
indicating that the E2F family can be subdivided into two functionally and structurally
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Figure 8.1
Three pathways for the nuclear accumulation of E2F
Nuclear accum ulation o f  E2F can occur throught three distinct mechanisms 
dependent upon either the alternatively spliced E region in DP (i), or the E2F subunit (ii), 
or an association with a pocket protein (iii)
The pocket protein mediated uptake allows a dominantly repressive form o f  E2F to enter 
the nucleus and repress transcription.
During cell cycle  progression, the activation o f  Cdks enables E2F to be released. 
Where the NLS is supplied by E2F or DP, the heterodimer presumably enters the nucleus 
in a transcriptionally active state.
distinct groups (Krek et al., 1994; Lukas et al., 1996; Mann and Jones, 1996; Zhu et al., 
1993). It is conceivable that the mechanism of nuclear accumulation of the two E2F 
sub-families may account for some of their distinct biological properties.
The DP family, too, can be divided into two sub-families based on their cellular 
location. Alternative splicing events in the RNA of the DP-3 gene produce four distinct 
DP-3 proteins. One of these processing events determines whether the E region is 
incorporated into the protein. DP-3 proteins that possess the E region, DP-3 a  and DP- 
30, were found in the nucleus when expressed in COS-7 cells, whereas those missing 
the E region, DP-3P and DP-3y, were found in the cytoplasm of COS-7 cells. A 
comparison of the E region of DP-3 with the same region in DP-1 indicated that DP-1 
lacks a domain analogous to E and, as expected, the protein was found in the cytoplasm 
when expressed in COS-7 cells. The conclusion here is that the E region influences the 
cellular location of the DP family members.
Although these data establish a dependence upon the E region for nuclear 
accumulation, they do not distinguish between the possibilities that the E region 
regulates nuclear entry or export. For example, it is possible that the E- variants can 
enter and exit nuclei, and that the presence of the E region impedes nuclear export, 
resulting in a net nuclear accumulation, possibly due to the E region being involved in 
tethering the DP to an insoluble nuclear structure.
DP-1 was observed to be cytoplasmic when expressed in COS-7 cells. 
However, co-expression of an NLS-containing E2F was sufficient to promote nuclear 
accumulation of all E- DP variants. This provides an explanation for the small amount
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of E- DP found in the cytoplasm of transfected COS-7 cells, as endogenous E2F would 
be able to transport an E- DP into the nucleus. It may also explain why endogenous 
DP-1 is nuclear.
This study has also shown that E2Fs devoid of an NLS, E2F-4 and E2F-5, are 
subject to two distinct mechanisms which regulate the levels of nuclear E2F, one in 
which the NLS is provided by the DP partner and the other where the NLS is supplied 
by the physical association of a pocket protein. E2F-4 and E2F-5 can accumulate in the 
nucleus through association with DP-3a or DP-3Ô but not with DP-1, DP-3p, or DP-3y, 
indicating that in the context of E2F, an E+ DP partner can provide the NLS. But, most 
of the E2F-4 and E2F-5 present in cell extracts is bound to E- DP-1 (Bandara et al., 
1993,1994; Girling et al., 1993; Wu et al., 1995). These studies have shown that this 
heterodimer is cytoplasmic when expressed in COS-7 cells. However, upon co­
expression with the pocket protein p i07, the heterodimer underwent nuclear 
accumulation. Surprisingly, co-expression of E la  did not alter the distribution of the 
E2F heterodimer even though the pocket protein-E2F complex was dissociated. 
Considering that E la  is an exclusively nuclear protein, this suggests that E la  may 
displace the pocket protein from the heterodimer after transporting the heterodimer into 
the nucleus. This would presumably result in release of a transcriptionally active E2F.
Subsequently, Allen et al., (1997) found that the mechanism of nuclear 
accumulation had a profound influence on the growth-regulating properties of E2F; 
when nuclear accumulation was E+ DP mediated, cells received a growth stimulus, 
whereas when it was mediated by the pocket protein complex, cell cycle progression 
could not ensue and cells accumulated in an arrested state. This suggests that a non-
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NLS-containing heterodimer, transported into the nucleus by a pocket protein is a 
transcriptionally inactive and dominantly repressive form of E2F, which maintains 
genes regulated by E2F binding sites in a transcriptionally inactive state. In conclusion, 
the mechanism of nuclear accumulation dictates the properties of the E2F heterodimer 
and the functional consequences on the cell cycle.
8-2. An alternatively spliced bipartite nuclear localisation signal in 
the E2F transcription factor
Chapter 3 identified a sequence of sixteen amino acid residues, the E region, 
which was required for efficient nuclear accumulation of DP. Although there was some 
similarity between the E region and the single-site SV40 Tag NLS, the functional 
properties of the E region did not satisfy the requirements for this type of NLS: 
Although necessary for nuclear accumulation of DP-3, the E region, by itself, was not 
sufficient to target a protein for nuclear accumulation. An additional basic region, 
located immediately C-terminal to the E region, was necessary to transfer a nuclear 
phenotype onto a non-nuclear protein.
Comparison of this sequence to previously defined NLSs suggested a closer 
resemblance to a bi-partite NLS rather than the single-site SV40 Tag- like NLS. 
Indeed, deletion of the basic region from an E+ DP resulted in a failure in nuclear 
accumulation, indicating that together, the E region and the basic region constitute a bi- 
paitite NLS in DP. As expected, removal of the basic region from DP also abolished its 
ability to transport a non-NLS-containing E2F into the nucleus.
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Unexpectedly, however, heterodimerisation of the basic deletion mutant DP with 
a NLS-containing E2F was insufficient to efficiently transport the DP into the nucleus. 
The data presented here showed that only 50% of co-transfected cells demonstrated co­
localisation of the heterodimer in the nucleus, with the other 50% of cells exhibiting 
nuclear E2F and cytoplasmic DP. This indicates that in 50% of these co-transfected 
cells, the basic region was required for nucleai' co-localisation, i.e. under certain 
circumstances, the basic region is involved either in nuclear retention of the DP after 
transport into the nucleus via E2F, or in regulating heterodimerisation in the cytoplasm, 
or in inhibiting export (Figure 8.2). It should be borne in mind however, that the basic 
deletion mutant could still heterodimerise with E2F and bind DNA in vitro, suggesting 
that these results propose a physiological regulatory mechanism involving the basic 
region, and not a mutation-derived iiTegularity in E2Fs ability to act as a transcription 
factor.
The theory that the basic region is involved in regulating nuclear accumulation 
of an E2F heterodimer was reinforced by experiments showing that the basic region in 
cytoplasmic DPs was still necessary for nuclear co-localisation with a NLS-containing 
E2F. Surprisingly, though, co-expression of pl07 was sufficient to transport the basic 
deletion mutant DP into the nucleus with E2F-1, implying that downstream E2F 
functions are regulated differently after pocket-protein mediated nuclear transport 
compared with free E2F nuclear transport.
Since the COS-7 cell line is transformed with SV40 large T antigen these 
transfections were also carried out in the parental cell line CV-1. T antigen was in fact
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cytoplasm
(i) Nuclear retention
(II) Cytoplasmic heterodimerisation
(III) Nuclear heterodimerisation
(Iv) Export regulation
DPAb
Figure 8.2 
Possible roles for the basic region of DP
(i) The basic region is required for the DP to be retained in the nucleus. The 
mutant DPAb will therefore be returned to the cytoplasm.
(ii) The basic region is required for heterodimerisation o f  E2F in the cytoplasm  
prior to nuclear translocation. The mutant fails to heterodim erise correctly and is 
therefore le ft in the cytop lasm  w h ils t the E2F tra n slo ca tes to the n u cleu s.
(iii) The basic region is involved in maintaining heterodimerisation o f  E2F in the 
nucleus. The mutant DPAb dissociates from the E2F partner and exits the nucleus.
(iv) The basic region is involved in the negative regulation o f  export o f  DP. 
Removal o f  the basic region results in the export o f  DP.
implicated in the phenotype of the E2F-1/ DP-3Ab since co-localisation of E2F-1 with 
basic deletion mutant DPs occuiTed in the nucleus of all double-stained CV-1 cells.
A major role of T antigen in transformation is in sequestering pocket proteins 
from E2F complexes to release free active E2F transcription factor. Considering that 
over-expression of the pocket protein pl07 in COS-7 cells reverts the phenotype of the 
mutant heterodimer to that of the wild type heterodimer, and the possibility that pl07 
may be titrating out T antigen implies a role for pocket proteins in a pathway resulting 
in nuclear accumulation of E2F.
Data were presented here to show that the Ela-mediated release of free E2F 
from E2F/pocket protein complexes resulted in nuclear retention of the heterodimer. 
Perhaps in 50% of the co-transfected cells, pocket proteins were bound to the E2F-1/ 
DP-30Ab heterodimer, and once in the nucleus, T antigen released the free heterodimer 
from the pocket protein. The observed phenotype could then be explained if the basic 
region was involved in tethering E2F in the nucleus. As only the DP component 
located to the cytoplasm, the basic region, in this scenario, must also be involved in 
maintaining an association between the DP and the E2F protein in the nucleus. 
Presumably then, if this were the case, co-expression of E la  with E2F-1/ DP-3ôAb in 
CV-1 cells would cause release of the DP component into the cytoplasm. On the other 
hand, as p i07 can titrate out T antigen, another unidentified function of T antigen, 
perhaps unrelated to pocket proteins, may have become abolished.
Alternatively, these results may show that two pathways exist for nuclear 
translocation. 50% of cells utilising a path that does not require the basic region and the
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other 50% utilising a pathway that relies on the basic region for efficient nuclear 
accumulation. One of these pathways is a target of T antigen, illuminating possible 
functions for the basic region in:
(i) Heterodimerisation of DP with E2F in the cytoplasm. T antigen prevents 
heterodimerisation therefore destroying a nuclear uptake vehicle for the non-NLS- 
containing DP.
(ii) Heterodimerisation of DP with E2F in the nucleus. T antigen causes the 
dissociation of the heterodimer once in the nucleus and the DPAb is returned to the 
cytoplasm.
(iii) Nuclear retention or export. T antigen causes release of DP from the 
heterodimer and DPAb is returned to the cytoplasm due to removal of the retention 
signal, or T antigen causes export of the mutant DP once dissociated from an E2F 
partner.
Pocket proteins mediate the other pathway of nuclear transport, which is not 
reliant on the basic deletion for import, nuclear retention or export. This alternative 
nuclear import pathway for the mutant heterodimer is not affected by the presence of T 
antigen.
In conclusion, these data support the theory that the basic region is involved in 
the nuclear accumulation of the E2F heterodimer. The basic deletion mutants behave as 
non-NLS containing components of the E2F transcription factor relying on
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heterodimerisation with a NLS-containing partner for nuclear accumulation. Assays in 
SV40 T antigen transformed cells have shown that the basic region plays a role in co­
localisation of the E2F heterodimer in the nucleus even when an NLS is supplied by the 
E2F component, but not if the NLS is supplied in trans by a pocket protein
8-3. 14-3-3 associates with the E2F transcription factor
The phenotypic characteristics of the basic deletion DP strongly suggested that 
the basic region was involved in an interaction between DP and another protein. 
Therefore, a yeast-two hybrid interaction trap assay was used to conduct an in vivo 
search for a gene encoding a protein that interacts with DP-3Ô but not with DP-3ôAb.
The epsilon isoform of the 14-3-3 family of signalling molecules was identified 
as a DP-30-binding partner, which required the presence of the basic region for the 
interaction in yeast. This interaction was then confirmed using several different 
methods. GST-14-3-38 was shown to bind to E2F-5 only when DP-35 was also present; 
no binding was observed with DP-30Ab. When immuno-blotting these pulled-down 
extracts for DP-3, the amount of DP-35 that was retained compared to the input level 
was far greater than the amount of DP-35Ab retained. A mammalian two-hybrid 
interaction assay confirmed the association in mammalian cells. A far greater 
association was evident between 14-3-3 and DP-35 than was seen between 14-3-3 and 
DP-1, indicating that specificity of the interaction occurs between members of the DP 
family. This is presumably due to sequence variations around the basic region in DP-1.
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Immunoprécipitation assays showed that an interaction between 14-3-3 and DP- 
30 required the basic region. A semi-endogenous in vivo IP showed that endogenous 
14-3-3 co-immunoprecipitated with exogenously expressed DP-35 (The anti-DP-3 
antibodies were unable to detect endogenous DP-3). Finally, 14-3-3 was shown to 
accumulate in the nucleus when expressed with E2F-5/DP-35. When expressed alone, 
14-3-3 is a cytoplasmic protein; therefore these data demonstrate that E2F can drive 14- 
3-3 into the nucleus, a result consistent with 14-3-3 having a physiological functional 
consequence on E2F.
At present, conventional 14-3-3 binding motifs, such as RSXpSXP (pS indicates 
a critical phosphoserine), have been identified in most 14-3-3 binding proteins (Yaffe et 
aL, 1997). However, there is no such consensus motif in DP. Crystal structure analysis 
predicts that 14-3-3 forms an amphipathic groove and its binding partners would 
possess an amphipathic helix to fit into the groove (Liu et aL, 1995; Xiao et aL, 1995). 
Therefore, it may be possible that removal of the basic region is altering the structure of 
DP-3 sufficiently enough to no longer be able to fit into the amphipathic groove.
Recently, another binding motif has been identified that consists of a serine 
cluster (Du et aL, 1996). Figure 7.1 showed that the basic region of the DP proteins is 
within a serine-rich region, supporting the idea that the basic region is involved in a 
direct interaction with 14-3-3. Mutation of more than one serine has been shown to be 
needed to disrupt the interaction of HDAC4 with 14-3-3 (Grozinger and Schreiber, 
2000). HDAC4 contains three 14-3-3 binding sites and mutation of individual or two 
14-3-3 binding sites was not sufficient to abrogate binding of 14-3-3, but mutation of all 
three serine residues to alanine abolished binding. Bearing this in mind, the negative
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results of the single-site in vitro mutagenesis chapter may not rule out phospho-binding 
at these sites. Perhaps 14-3-3-dependent effects upon E2F are not abolished when only 
one serine is mutated to alanine. Moreover, the lack of phosphorylation at the mutated 
sites may be overcome by the presence of negatively charged residues sun'ounding the 
basic region. Testing the binding of DP-35 to 14-3-3 under alkaline phosphatase 
treatment would be useful in determining whether the interaction is phosphorylation 
dependent. Nonetheless, several observations have led to the notion that 14-3-3 is also 
capable of interacting with unphosphorylated ligands, for example Raf-1 (Muslin et ah,
1996).
8-4. Functional consequences of the 14-3-3-E2F interaction
The 14-3-3 proteins, which constitute a highly conserved family of homo- and 
heterodimeric molecules, associate with a number of different signalling molecules. 
They have been proposed to be important in controlling intracellular signalling 
pathways by acting as molecular scaffolds or platforms that bring together signalling 
molecules. Considering the broad range of partners for 14-3-3, a specific cellular 
function for these proteins has not been defined; rather they have been suggested to act 
as general biochemical regulators. With this in mind, this work set out to realize what 
aspect of E2F function 14-3-3 modulates
This work has shown that 14-3-3 has the ability to regulate E2F site-dependent 
transcription. Co-expression of 14-3-3 with E2F5/ DP-3p or E2F5/ DP-35 heterodimers 
repeatedly caused a three to eight-fold increase in the level of E2F site-dependent
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transcription. This effect was not observed in heterodimers containing the basic 
deletion mutant DP, supporting the previous data showing that the basic region was 
required for an interaction with 14-3-3. These data also demonstrated that the failure of 
the mutant heterodimer to respond to 14-3-3 was not due to the lack of a NLS in the 
heterodimer as both the cytoplasmic heterodimer E2F-5/ DP-3|3, and the nuclear 
heterodimer E2F-5/ DP-35, were responsive to 14-3-3.
Strildngly, opposite effects were observed for 14-3-3 on an E2F-1 heterodimer. 
14-3-3 diminished the transcriptional activity of an E2F-1/DP-35 heterodimer almost to 
background levels but increased the activity of an E2F-1/ DP-35Ab heterodimer. These 
data suggest that 14-3-3 effects on transcription aie heterodimer specific. This result 
may correlate with differences in the functional properties of E2F-1 and E2F-5 (Wang 
et al 2000). Although both proteins induce proliferation in transgenic models, unlike 
E2F-1, E2F-5 can not induce apoptosis, and this correlates with the differential abilities 
of these two species to stimulate pl9ARF expression in vivo. Unlike E2F-1 transgenic 
mice, E2F-4 (and presumably also E2F-5) transgenic mice develop skin tumours with a 
decreased latency and increased incidence compared to controls. These findings 
demonstrate that while the effects of E2F-1 and E2F-5 on cell proliferation in vivo are 
similar, their apoptotic and oncogenes properties are quite different. Assumedly, 14-3-3 
provides a growth stimulus by increasing the activity of the E2F-5 heterodimer and 
concuiTently shutting off E2F-1 -dependent transcription in order to prevent an apoptotic 
response.
Surprisingly, higher transcriptional activity was not the result of an increase in 
heterodimer protein levels. Although the E2F-5/ DP-35Ab heterodimer failed to
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activate transcription as highly as the E2F-5/ DP-35 heterodimer did, western blot 
analysis of the extracts used for the reporter assay showed that removal of the basic 
region resulted in higher expression levels of E2F-5 and DP proteins. Consistent with 
this paradox, increased transcriptional activity of E2F-5/DP caused by the expression of 
14-3-3 also resulted in a decrease in heterodimer protein levels. These results leads to 
the conclusion that the binding of DP-35 to E2F-5 causes stabilisation of both protein 
levels, presumably due to DNA binding, removal of the basic region results in greater 
stabilisation of the protein levels, and 14-3-3 causes an increase in transcriptional 
activity of the wild type heterodimer whilst decreasing the heterodimer protein levels.
The greater abundance of protein levels of the mutant heterodimer was shown to 
be due to an increase in the half-life of both components of the heterodimer. Removing 
the basic region form both the nucleai* DP-35 and the cytoplasmic DP-3(3 resulted in an 
increase in the half-life of the DP protein. This demonstrates that the increase in 
stability was not due to the cytoplasmic location of the mutant DP. Also, the mutant DP 
had the ability to confer an increase in stabilisation onto an E2F-5 partner. An increase 
in the half-life of E2F-5 was observed when co-expressed with a basic region-deleted 
DP-3 compared to when expressed with the wild type DP-3 partner.
Addition of 14-3-3 to the wild type heterodimer resulted in a decrease in half- 
life of E2F-5 consistent with the theory that 14-3-3 promotes the degradation of the E2F 
transcription factor. As the 14-3-3 was unable to affect the half-life of E2F-5 in a 
heterodimer with the mutant DP-3, the basic region must be necessary for 14-3-3 to 
exert its degradation effects on E2F-5.
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Using a proteasome-specific inhibitor, LLnL, showed that DP-38 was subject to 
degradation via the ubiquitin mediated pathway. Proteins targeted for degradation via 
this pathway become stabilised in the presence of the inhibitor, allowing quantitative 
analysis of protein stability changes. Protein levels of the basic deletion mutant DP-3 
did not increase in the presence of the inhibitor indicating that it was not subject to 
degradation. As expected, protein levels of DP-38 rose when expressed with an E2F 
partner, however, when co-expressed with 14-3-3, the relative abundance of DP-35 
protein decreased. This effect of 14-3-3 was shown to be dependent upon the presence 
of the basic region as the mutant heterodimer protein levels failed to increase in the 
presence of the proteasome inhibitor. These results indicate that stabilisation of E2F 
components as a result of heterodimerisation is due to a decrease in ubiquitin- 
proteasome-mediated degradation. They also indicate that the association of the 
heterodimer with 14-3-3 causes an up-regulation of ubiquitin-proteasome-mediated 
degradation of the heterodimer. Since the mutant DP35Ab stability did not change, 
whether expressed alone, as a heterodimer, or in the presence of 14-3-3, indicates that 
the basic region is instrumental in 14-3-3-mediated targeting of the heterodimer to the 
ubiquitin-proteasome-mediated degradation pathway.
Protein degradation within cells is a very tightly regulated multi-step process, 
believed to be initiated by site-directed ubiquitination of target proteins. Ubiquitin- 
mediated proteolysis is a prominent mechanism regulating transcription factor function 
that keeps the intracellular levels of these proteins low and responsive to environmental 
stimuli, e.g. Jun (Treier et aL, 1994), p53 (Chowdary et aL, 1994), and Myc (Salghetti 
et aL, 1999). Despite the importance of this process, however, the mechanisms 
governing substrate recognition are poorly understood. How 14-3-3 targets E2F for
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degradation is an important question that warrants further investigation. In accordance 
with the theory that 14-3-3 targets E2F for degradation, it has been shown that nitrate 
reductase in spinach leaves is also targeted for degradation after associating with 14-3-3 
(Weiner and Kaiser, 1999).
A major draw back of this work has been the inability to measure the half-life of 
the endogenous E2F heterodimers. Also to be considered is whether the E2Fs should be 
less stable in cell lines lacking members of the pRB family, and whether the E2Fs have 
shorter half-lives in the S phase of the cell cycle, when the pRB family members are 
phosphorylated at high stoichiometry.
It is not uncommon for degradation signals to overlap with other functional 
domains within the target protein. Interestingly, Salghetti et aL, (2000) have found that 
protein destruction elements in transcription factors overlap with transcriptional 
activation domains. This suggests that cells have evolved a mechanism whereby potent 
transcriptional activators would be destroyed. Such regulation may be important for 
rapid reprogramming of transcriptional patterns, to limit activation by any one single 
activator or to prevent accumulation of excess activator that could lead to ‘squelching’ 
of the basal machinery. Activators can stimulate transcription by recruiting components 
of the ubiquitin-proteasome pathway that subsequently modify histones, basal factors, 
and ultimately the activators themselves (Salghetti et aL, 2000). The basic region, 
although not part of a transactivation domain, is very close to the DNA binding domain. 
Although mutation of the basic region did not affect DNA binding or 
heterodimerisation of E2F, transcriptional activity of the mutant heterodimer was
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reduced 50% compared to the wild type heterodimer, signifying a requirement for this 
region for efficient activation.
Perhaps of significance to these results is the discovery that histone deacetylases 
have been found to associate with 14-3-3 proteins. HDAC4 and HDAC5 associate with 
14-3-3 resulting in sequestration of these proteins in the cytoplasm (Grozinger and 
Schreiber, 2000). This prevents HDACs translocating to the nucleus where they repress 
gene expression. This role for 14-3-3 proteins may explain the increase in 
transcriptional activity if 14-3-3 is brought into the nucleus with DP-3 then transports 
the HDAC out of the nucleus (Figure 8.3).
The 14-3-3-mediated degradation of E2F was shown to be necessary for cell 
cycle progression. The E2F/DP-3Ô heterodimer caused an increase in S phase with a 
concomitant decrease in G l, as would be expected from a cell proliferation inducer. 
Removal of the basic region disrupted the ability of the heterodimer to promote cell 
cycle progression and cells became arrested in S-phase. This suggests that cells with 
high levels of DP protein are impaired in their ability to exit S phase. Degradation of 
the E2F transcription factor, mediated by 14-3-3 through the basic region of DP3, is 
necessary before cells with high levels of E2F can progress through the cell cycle. This 
provides an explanation for the appaiently paradoxical reporter assay results. High 
levels of the heterodimer cause cells to aiTest and possibly apoptose, this would result in 
a lowering in E2F-site dependent transcription. Allowing cells to cany on cycling 
restores E2F transcriptional activity.
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Figure 8.3
Model showing how 14-3-3 may promote degradation and increase transcriptional 
activation of E2F
14-3-3 and E2F co-localise to the nucleus. 14-3-3 transports HDAC to the cytoplasm, 
thus removing transcriptional repression. Excess E2F is targeted for ubiquitin-proteasome 
m ed ia ted  d egrad ation  to p reven t sq u e lc h in g  o f  tra n scr ip tio n  m ach in ery .
The down-regulation of E2F activity in the S phase of the cell cycle has been 
shown to be essential in order to allow cells to enter G2 (Krek et al 1995). One possible 
explanation for this is that certain E2F regulated genes must be down-regulated in order 
for cells to enter G2, and the constitutive activation of such genes would be deleterious 
for the cell. In agreement with such a suggestion is the observation that deregulated 
expression of E2F-1, -2, -3 or nuclearly expressed E2F-4 all induce S phase followed by 
apoptosis (Helin 1998). The inactivation of E2F-1, -2 and ~3, but not E2F-4 and -5, 
DNA binding activity can be achieved by cyclin A dependent Idnase activity (K ek et 
aL, 1995), and this regulatory mechanism is therefore sufficient for down regulating 
E2F activity generated by E2F-1, -2 and -3  but not by E2F-4 and -5. Expression of 
E2F-1 occurs late in G l, reaching its maximum levels as cells enter S phase. In 
contrast, E2F-4 and E2F-5 mRNA is constitutively expressed throughout the cell cycle 
with up to three-fold higher levels in mid G l, which fall again by S phase (Sardet et aL,
1995). Since E2F-4 and E2F-5 do not associate with cyclin A, they must rely on 
another method for inactivation. 14-3-3-directed ubiquitin-mediated degradation is one 
such possibility.
14-3-3 proteins often regulate intracellular localisation of their binding partners. 
For example, phosphorylation of Cdc25 by Chkl kinase creates a binding site in Cdc25 
for 14-3-3 (Peng et aL, 1997; Sanchez et aL, 1997). The subsequent 14-3-3 binding to 
Cdc25 markedly reduces the nuclear import rate of Cdc25, allowing nucleai* export 
mediated by an NES present in the N-terminus of Cdc25 to predominate (Yang et aL, 
1999). Since Cdc25 has a functional NLS that lies adjacent to the site of 14-3-3 
binding, 14-3-3 binding might sterically block access of Cdc25 to the nuclear import 
machinery (Kumagai and Dunphy, 1999; Yang et aL, 1999). Although the basic region
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is involved both in nuclear import, and 14-3-3 association, 14-3-3 does not prevent 
nuclear accumulation of the heterodimer as is reported for some other 14-3-3 
interactions. 14-3-3 did not appear to have any influence on the cellular location of DP- 
3. In fact, co-expression of the heterodimer with 14-3-3 resulted in nuclear 
translocation of the 14-3-3 protein. This indicates that either 14-3-3 does not bind 
directly with the basic region, or both 14-3-3 and the nuclear import machinery can 
associate with the basic region simultaneously. Recently Seimiya et aL, (2000) have 
reported 14-3-3 mediated nuclear accumulation of hTERT telomerase, thus supporting 
the idea that 14-3-3 can function in the nucleus as well as in the cytoplasm.
What triggers the association of 14-3-3 with DP-3 is unknown. Many 14-3-3 
interactions are induced by extra-cellular stimuli, e.g. DNA damage (Hermeking et aL,
1997) or platelet-derived growth factor (Autieri et aL, 1996). More efficient binding 
between E2F and 14-3-3 may require the coixect conditions.
8-5. Overall conclusions
To fully understand the role of each individual member of the E2F and DP 
family members in gene expression and cell cycle control, it will be necessary to 
document which factors associate with one another in the cytoplasm under specific 
growth conditions, which of the resulting E2F/ DP complexes enter the nucleus and 
interact with specific subsets of cellular promoters, and how the distribution of each of 
these distinct complexes changes during the cell cycle. This study aims to move closer 
to realising these questions by defining a bipartite NLS in DP, which will direct nuclear
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accumulation of a non-NLS containing E2F partner. The basic region of the bipartite 
NLS is also involved in directing the nuclear accumulation of an NLS-containing E2F 
heterodimerisation partner. This study has also identified 14-3-3 as a regulatory protein 
that can influence E2F activity. However, in contrast to the pRB family, where the 
association with E2F is direct and occurs through the C-terminal region in each E2F 
family member, the interaction of 14-3-3 depends upon the DP family member. This 
view is supported by a variety of data presented in this study, including the isolation of 
14-3-3 with a DP ‘bait’ in the yeast two-hybrid system, the in vitro physical interaction 
between 14-3-3 and DP-3, the mammalian two hybrid assays, the DP-dependent 
regulation of E2F activity by 14-3-3 and the DP-directed intracellular localisation of 14- 
3-3. Moreover the analysis of a mutant derivative of DP-3, lacking the ability to form 
an interaction with 14-3-3, has defined a region in DP necessary for 14-3-3 directed 
ubiquitin-proteasome mediated degradation. This pathway has been proposed as a 
means of lowering abnoimally high levels of E2F to allow S phase progression.
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